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Abstract 
Ent-11 a-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) is a chemical compound 
extracted from a Chinese herbal medicine, Pteris semipinnata L. Apoptotic effect 
induced by 5F has been documented in several in vitro tumor cell lines but not yet 
been tested in vivo. In this study, the therapeutic effects of 5F as well as possible side 
effects were investigated in mouse models of hepatocellular carcinoma (HCC) and 
lung cancer. 12mg/kg, 24mg/kg, and 48mg/kg of 5F were given to mice for 12 weeks 
(HCC model) or 18 weeks (lung cancer model). The result showed that 5F was 
effective in reducing the total volume of tumors in both mice models. 5F treatment 
alone (24 & 48mg/kg) and low dose of 5F (12 & 24mg/kg) in combination with 
5-fluorouracil were most effective in reducing the total tumor volume in mice. 
Immunohistochemical investigation demonstrated that 5F induced apoptosis and 
suppressed cell proliferation in vivo in both models significantly, as shown by the 
TUNEL assay and PCNA index respectively. Treatment of 5F up-regulated several 
pro-apoptotic signaling molecules including Bax, Bak, and inducible nitric oxide 
synthase (iNOS). The expression of anti-apoptotic nuclear factor kappa B (NF-kappa 
B) and Bcl-2 was decreased by 5R Phosphorylation of I-kappa B was reduced in 
mice with 5F treatment. Extracellular kinase 1 and 2 (Erkl/2) showed reciprocal 
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expression in tumor tissues of the mice treated with 5F. The side effect of 5F was 
mild with slight fur loss. No mice died due to intolerance to 5F. Liver function was 
not deteriorated by 5F, while slight upset in renal function was observed. In 
conclusion, this study demonstrated that 5F alone was effective against HCC and 
lung cancer in-vivo. The effect of 5F was dose-dependent. At high concentrations of 
24mg/kg and 48mg/kg 5F induced apoptosis in-vivo significantly. 5F was also 
effective at low doses of 12mg/kg and 24mg/kg in combination with 5-FU. Lastly, 5F 
did not result in serious side-effects. 
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論文摘要 




12mg/kg , 2 4 m g / k g或 4 8 m g / k g濃度的 5 F，作長達 1 2週（肝癌模型）或 1 8 
週（肺癌模型）的治療。結果表明，5F有效地減少在小鼠模型中腫瘤的總量。 
高劑量的5F ( 2 4 和 4 8 m g / k g ) 和低劑量 5 F ( 1 2和2 4 m g / k g )配合5 -氟尿啼卩定 
( 5 - F U )能最有效地減少總腫瘤體積。免疫組織化學的T U N E L法和P C N A指 
% 
數測試的結果表明，5F能顯著地在體内誘導細胞调亡和抑制細胞增殖。5F能提 
高一些促调亡信號分子包括B a x � B a k �誘導型一氧化氮合酶（ i N O S )的表達。 
5F亦能通過減少I-kB的隣化激活，從而減少核因子-KB ( N F - K B ) 的生成 � 5 F 




濃度（ 2 4 m g / k g和 4 8 m g / k g )治療效果顯著。 5 F在低劑量 ( 1 2 m g / k g和 2 4 m g / k g ) 
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Chapter 1: Introduction 
Liver cancer and lung cancer are major health problems among Asian populations. 
Both cancers had been enlisted among the ten most frequent sites of cancer 
occurrence in the Asian populations of the United States (Center of Disease Control, 
2005). In Hong Kong, lung cancer and liver cancer are the first two leading causes of 
cancer death in both men and women, sharing 50% of the total cancer deaths 
(HKSAR, Hospital Authority, 2006) (P<0.05). Novel chemotherapy agents of the 
two cancers have been interests of researchers over decades. 
1.1. Liver cancer 
Liver cancer is a major cause of cancer death in Asian populations (WHO, 2005). In 
the United States, liver cancer has an incidence rate in Asian population twice as 
other races (CDC, 2005). In Hong Kong, liver cancer is the second highest in cancer 
mortality rate, following lung cancer (HKSAR, HA, 2006). 
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1,1,1, Hepatocellular Carcinoma (HCC) 
Among major types of liver cancer, hepatocellular carcinoma (HCC) (Fig. 1) is 
becoming a major topic in liver cancers. Previous study shows that diagnosed case of 
HCC is increasing in the United States with an age-shift towards the younger 
populations (El-Serag & Mason, 1999). The low chance of curative treatment results 
in poor prognosis of HCC (Yuen et al., 1999). Cirrhosis, hepatitis B virus (HBV) and 
hepatitis C vims (HCV) are the major risk factors of HCC (Tsukuma et al, 1994). 
HCC develops from cirrhosis, which is common at late viral infection (Kiyosawa et 
al., 1991). Major curative method of HCC is surgical resection followed by liver 
transplantation. Massive studies have been carried out in developing novel 
chemotherapy/chemoprevention agents against HCC, but facing difficulties on the 
resistance of apoptosis by the HCC cells (Bruix et al., 2006). Most common systemic 
chemotherapies are not effective against HCC (Bruix et al” 2006). In the progression 
of HCC, besides the down-regulation of major pro-apoptotic signaling molecules, 
imbalance of pro- and anti-apoptotic signaling molecule regulations is triggered by 
the over-expression of anti-apoptotic factors (for review: see Fabregat et al, 2007). 
As conventional chemotherapeutic agents are not effective against HCC, traditional 
herbal medicines which are proclaimed or believed to be anti-hepatitis or 
2 
anti-inflammatory are becoming more popular topic. Studies on the extracts of those 
herbs are increasing apparently and their results are promising (Shiota et al., 1999; 
Yang et al., 2008). 
« 
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Figure 1: Liver showing hepatocellular carcinoma (HCC) 
Adapted from http://pathweb.uchc.edu 
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1.2. Lung Cancer 
Lung cancer (Fig. 2) is widely known with high mortality rate throughout the world. 
In the United States, lung cancer is the leading cause of cancer death, with an 
incidence of around 200,000 new cases per year in the both sex (WHO, 2005). More 
than 150,000 people died of lung cancer in the year 2005 in the United States (CDC, 
2006). Vast majority of lung cancer cases are related to tobacco smoking (CDC, 
2001). Tobacco related nitrosamine from smoking has been proved to be 
carcinogenic to laboratory animals (Hoffmann et al., 1984; Riverson et al, 1988). 
Lung cancer can be divided into two main types: small cell lung carcinoma (SCLC), 
and non-small cell lung carcinoma (NSCLC) which contains several subtypes (Travis 
et al, 1995). Both types are different in the biology, therapeutic response and 
prognosis (Shivapurkar et al” 2003). The study of Soini et al. showed that SCLC was 
significantly differed than NSCLC in terms of apoptotic index (Soini et al.，1998). 
Besides, the mechanism of the two types is very different from each other (Joseph et 
al., 1999). The prognosis of lung cancer is poor due to complexity of resistance 
against apoptosis (Shivapurkar et al.，2003). Generally, SCLC responses to 
anti-cancer drugs and radiation therapy while NSCLC resists to similar medical 
interventions (Owens & Abeloff，1985). Adenocarcinoma is a major subtype of the 
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NSCLC. This type of carcinoma is strongly associated with nicotine compounds in 
tobacco (Castonguay et aL, 1983; Hecht et al, 1983). Similar to HCC, 
adenocarcinoma down-regulates common pro-apoptotic molecules and 
over-expresses major anti-apoptotic signaling proteins to protect from cell death 
(Joesph, 2000). 
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Figure 2: Lung showing adenocarcinoma 
A major type of lung cancer. Adapted from http://pathweb.uchc.edu 
7 
1.3. Pteris semipinnata L. 
Pteris semipinnata L. (PsL) (Fig. 3) belongs to family of Pteridaceae under the order 
ofPteridales (USDA, ARS, 2009). In general knowledge, PsL is known as "brake". 
PsL is an herb widely distributed at the southern part of China (Chinese Academy of 
Science, 1959). This herb has been used to treat hepatitis, enteritis and snake bites as 
Chinese Medicine (Ding et al” 1982). It was reported that PsL extracts contain a 
mixture of diterpenes and sesquiterpene in the late 80’s (Murakami & Tanaka，1988). 
A total of five components had been successfully separated by ethanolic extraction 
method (Zhang et al, 1997; Zhang et aL, 1999). Among the five compounds, three of 
the compounds were confirmed by two-dimensional nuclear magnetic resonance that 
an anti-tumor related a-methylene cyclopentanone were found (Zhang et al, 1997; 
Zhang et al, 1999). All three components had showed activity to inhibit the growth 
of human promyelocytic leukemia cells (HL-60), gastric adenocarcinoma cells 
(MGC-803), human nasopharyngeal carcinoma cells in low differentiation (CNE-2Z), 
and human liver adenocarcinoma cells (BEL-7402) in-vitro (Zhang et al” 1997; Li et 
al, 1999; Zhang et al, 1999). One of the isolated components is 
Ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F). 
8 
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Figure 3: Photo of Pteris semipinnata L. 
This photo was taken in Woo Kau Teng, Hong Kong. 
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1.4. Extract ofPsL: 5F 
Ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) is one of the compounds 
isolated from PsL that contains anti-tumor activities (Zhang et ai, 1997; Li et al” 
1999; Zhang et al., 1999; Chen et al, 2004; Liu et al” 2005). The compound is 
obtained by ethanolic extraction followed by methanol-chloroform elution (Zhang et 
al, 1997). The chemical structure contains a-methylene cyclopentanone which is 
highly related to activation of the compound's anti-tumor activity (Fig. 4) (Zhang et 
al” 2007). Further studies revealed that 5F was capable of inducing apoptosis via 
intrinsic (mitochondrial) pathway (Chen et al” 2004). 5F has showed activation and 
up-regulation of mitogen-activated protein kinase (MAPK) family proteins in human 
chronic myelogenous leukemia cells (K562) (Wang et al, 2002). This enlightens the 
mechanisms of 5F-induced apoptosis. In later literature, the up-regulation of 
inducible nitric oxide synthase (iNOS) and p38 MAPK with a down-regulation of 
Bcl-2 and Bcl-xL in a nuclear factor kappa B related mechanism was observed in 
human colonrectal cells (HT-29) (Chen et ai, 2004). Identification of involvement of 
a powerful pro-apoptotic molecule, Bax, in gastric cancer cells containing wild type 
p53 (MKN-45), and generation of reactive oxygen species (ROS) further solidified 
the cell death-inducing property of 5F (Liu et al, 2005). On the other hand, different 
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family members of the MAPK molecules, which activated by 5F, may have 
contradictive effects in apoptosis (Liu et al., 2005), 5F-induced c-Jun N-terminal 
kinase (JNK) activation caused a block of cell cycle during G2 phrase, while p38 and 
extracellular signal-related kinase (Erkl/2) were also activated, however, as survival 
factor in anaplastic thyroid carcinoma cells-wild type p53 (FRO) (Liu et al., 2005). 
Inducing cell death of malignant cells through apoptosis to achieve cancer 
chemoprevention and chemotherapy via dietary or pharmaceutical manipulation is 
one of most popular strategies investigated recently. Anti-tumor activity of 5F shows 
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Figure 4: Chemical structure of 5F. 
Red circle indicates the a-methylene cyclopentanone structure which is strongly 
related to the activation of the apoptotic properties of 5F 
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1.5- Animal models in chemotherapy 
researches 
1.5.1. Model of HCC 
HCC models are set up by administrating a HCC carcinogen into designated animals 
(Dunsford et al, 1989; Tamano et ai, 1994; Ahn et al, 1999). In HCC mouse model, 
three strains of mice have been extensively used including C3H, C57, and BALB. 
Among the three, C3H strain (Fig. 5) has shown highest yield of HCC tumors 
development with administration of diethylnitrosamine (DEN) via intra-peritoneal 
injection to mice juveniles, compared to C57 and BALB strain with DEN (Lee et ai, 
1991). Prolonged oral administration of DEN at low concentrations has also been 
proofed to be effective in developing HCC in C3H mice, with a regular oral 
administration of Phenobarbital (PB) (Lee et al, 1989). DEN induce tumor in a 
way similar to aminoazo dyes. Hepatocellular degeneration was observed and 
transformation of the degenerated hepatocytes to precursors of hepatoma was 
confirmed by histological techniques (Ha, 2001). Simplicity of administration, with 
high incidence of tumor development makes DEN-C3H mice combination a good 
model for HCC studies. 
1 3 
Figure 5: C3H/HeJ mouse. 
A strain of mouse has high incidence of developing HCC by liver carcinogen DEN. 
Adapted from http://www.criver.com 
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1,5,2. Model of lung cancer 
Major lung cancer mouse model involves the use of 4-(Methylnitrosamino)-
1 -(3-pyridyl)-1 -butanone (NNK) in A/J mice (Fig. 6). The administration ofNNK to 
A/J mice is one single dose of carcinogen at six weeks age (Belinsky et al, 1992), 
much simpler than continuous administration in other strains like C3H and BALE 
(Belinsky, 1992). NNK is a main ingredient of tobacco products, including 
mainstream smoke, sidestream smoke and unbumed tobacco (Hoffmann et al, 1979). 
Activated NNK leads to formation of promutagenic product O^-methylguanine 
(O^MG), with reacts with DNA to form a bulky adduct (Belinsky et al, 1989). The 
rate of tumor formation is widely known to be high in A/J mice. It thus makes the 
combination a suitable choice in studying lung cancer. 
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Figure 6: A/J mouse. 
This strain of mouse has a high incidence of lung adenomas, and lung tumors readily 
develop in response to carcinogens. Adapted from http://jaxmice.jax.org 
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1.6. Apoptosis: Significance of 
programmed cell death 
Apoptosis, programmed cell death, is an important mechanism that maintains cell 
homeostasis in development (Wylie et a l , 1980; Arends & Wyllie，1991). The 
occurrence of apoptosis in cells is orchestrated by a complex network of signaling 
pathways. The main switch of apoptosis is controlled by a family of cysteine 
protease known as caspases (Stennicke & Salvesen, 2000). A total of 14 caspases 
have been identified. Caspases exists in cells as inactive zymogens, and are activated 
by proteolytic processing followed by formation of active tetramers (Shivapurkar et 
al” 2002). Caspase (CASPs) can be subdivided according to their functional nature: 
as initiator triggering apoptosis process upstream, or as effector executing apoptosis 
downstream. Initiator caspases, such as CASPS, CASP9 and CASPIO, are activated 
after receiving a pro-apoptotic stimulus and activate effector caspases, such as 
CASPS, CASP6 and CASP7, to execute the cell death process. Headed by CASPS and 
CASP9, apoptotic mechanisms can be divided into two main pathways: 
death-receptor mediated (extrinsic) pathway by CASPS and mitochondria-mediated 
(intrinsic) pathway by CASP9 (Green & Reed，1998; Thomberry & Lazebnik, 1998; 
Gupta, 2001). 
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1.6,1. The extrinsic pathway 
The extrinsic pathway, or known as death-receptor pathway, involves responses of 
death receptors to death inducing ligands (Ashkenazi & Dixit, 1999; Bodmer et al, 
2000). Examples of these death inducing ligands are tumor necrosis factor alpha 
(TNF-a), Fas ligand (FasL), TNF related apoptosis-inducing ligand (TRAIL). These 
death inducing ligands binds to respective specific reseptors such as TNF-Rl (for 
TNF-a), FAS (for FasL), DR4 or DR5 (for TRAIL). The death signal of these 
molecules will promote formation of complex between an adaptor molecule, FADD, 
and precursor of CASPS, procaspase 8 (Shivapurkar et al., 2002). In the resulting 
complex, death inducing signaling complex (DISC), CASPS is activated by 
cross-proteolysis. This can either activates of downstream caspases directly or 
promotes the release of cytochrome c in a truncated-Bid (tBid) mediated manner to a 
execute apoptosis (Li et al, 1998; Luo et al., 1998; Scaffidi et al., 1998). 
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1.6.2, The intrinsic pathway 
The intrinsic pathway mainly involves various extra- or intra-cellular signals that 
exert the effects on the power house of cells, the mitochondria. These signals induce 
the dysfunction of mitochondria, alter the mitochondrial membrane permeability and 
release of pro-apoptotic factors such as cytochrome c, second mitochondria-derived 
activator of caspase/direct inhibitor-of-apoptosis-protein binding protein with low pi 
(SMAC/DIABLO), apoptosis-inducing factor (AIF), endonuclease G, etc., into the 
cytosol. Cytochrome c promotes formation of apoptosome, a caspase-activation 
complex of APAF-1 and CASP9 (Adrain & Martin，2001; Schafer & Kombluth，2006) 
(P<0.05). SMAC/DIABLO binds to inhibitor-of-apoptosis-protein (lAP) which 
inhibits activated CASP9 in apoptosome (Du et aL, 2000; Verhagen et al, 2000). AIF 
and endonuclease G promote chromatin condensation and DNA fragmentation in 
nucleus (Susin et al, 1999; Li et aL, 2001). 
Intra-cellular signals that regulate the mitochondria pathway are mainly, but not 
limited to, the Bcl-2 family proteins. The Bcl-2 family is defined by molecules that 
process up to four Bcl-2 homology (BH) domains including BHl, BH2, BH3, and 
BH4 (Adams & Cory，1998; Kelekar & Thompson, 1998). The conservation of the 
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BH4 domain is related to the anti-apoptotic properties of the Bcl-2 family molecules 
which pro-apoptotic family members are less conserved in this region (Gross et al, 
1999). Previous studies reveals that the deletion and mutation of the BH3 domains 
will extinguish the pro-apoptotic properties of the pro-apoptotic members which is 
further supported by the discovery of a subset of pro-apoptotic BH3-domain-only 
molecules like Bad (Kelekar et al” 1997). The Bcl-2 family of molecules includes 
both pro- and anti-apoptotic members, for example, Bcl-2 and Bcl-xL are widely 
known as anti-apoptotic while Bax, Bak, and Bid are generally accepted as 
pro-apoptotic members. In normal cells, anti-apoptotic members are mostly found as 
integral membrane proteins in mitochondria membrane, endoplasmic reticulum (ER), 
or nuclear membrane (Hockenbery et al., 1990; Krajewski et al, 1993; de Jong et al, 
1994; Zhu et al” 1996) (P<0.05). On the other hand, a majority of pro-apoptotic 
Bcl-2 family members are initially situated in cytosol or cytoskeleton before 
receiving death signals (Hsu et al., 1997; Gross et al” 1998; Puthalakath et al” 1999). 
Upon receiving death signal, translocation of pro-apoptotic Bcl-2 family members 
like Bax, Bak from cytosol to mitochondria is promoted. As a result the membrane 
permeability of mitochondria (A^m) is changed. Cytochrome c and 
apoptosis-inducing factor (AIF) is then released into cytosol. Cytochrome c activates 
CASP3 and CASP9, which results in cell death. AIF translocates into the nucleus, 
2 0 
causing chromatin condensation and mass DNA fragmentation which, finally, lead to 
caspase-independent apoptotic cell death (Green & Reed, 1998). Induction of 
apoptosis is a critical factor to determine the capability of anti-tumor agents or 
chemotherapeutic drugs (Smets, 1994). In recent years, interest of this topic has been 
focused on the mechanisms of potential chemotherapeutic drugs that induce 
apoptosis in vitro or in vivo. 
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1.7. Apoptotic molecules related to 
this study 
1.7.1, Bcl-2 family 
1.7.1.1. Bax 
Bax is a member of Bcl-2 family characterized by its pro-apoptotic ability (Gross et 
al” 1999). Bax activation involves subcellular translocation and dimerization. 
Majority of Bax molecules are found in cytosol or loosely attached to mitochondrial 
membranes in a form of monomeric molecules. Upon receiving death stimulus, 
monomeric Bax molecules in the cytosol translocate into the mitochondria. 
Dimerization of Bax molecules takes place at the mitochondrial membrane and 
becomes the integral membrane protein (Wolter et al., 1997). However, the 
dimerization of Bax may not be the only mechanism to induce apoptosis. Previous 
studies indicate that an enforced chimeric Bax dimer molecules can still translocate 
to mitochondria and are cell death-inducing even in the presence of anti-apoptotic 
Bcl-xL (Gross et al., 1998). In the same study, the chimeric Bax showed apoptotic 
activity even without release of cytochrome c as well as under pan-caspases 
inhibition (Gross et ai, 1998). Thus activation of Bax is associated with cell death in 
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various ways. These ways include normal wild-type dimerization, enforced 
activation in monomer form even in the presence of survival factors, cytochrome 
c-independent, and downstream pan-caspase inhibition, indicating that Bax 
pro-apoptotic activity is multi-effector driving. This unique and interesting feature 
makes Bax an extraordinary import molecule in the mitochondrial-mediated 
apoptosis pathway. 
1.7.1.2. Bcl-2 
Being the first identified member of the family, Bcl-2 is known as the leading 
molecule among the anti-apoptotic members of the family. It is widely accepted that 
Bcl-2 promotes cell survival instead of cell proliferation in the process of tumor 
development (Hanahan & Weinberg, 2000; Johnstone et al., 2002). Bcl-2 mainly 
impairs the balance of apoptosis in developing tumors (Vaux et al, 1988). 
Over-expression of the Bcl-2 as well as other anti-apoptotic members in a similar 
structure such as Bcl-xL is commonly seen in tumor cells that are resistant to 
apoptotic-inducing agents (Adams & Cory, 2007). Studies that show Bcl-2 and 
Bcl-xL can inhibit activation of Bax support the theory (Gross et al, 1998). Bcl-2 is 
initially heavily localized in mitochondrial membrane as an integral protein so that 
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create resistance to translocation of Bax from the cytosol to the mitochondrial 
membrane (Gross et al” 1999). Besides of cell death prevention, Bcl-2 can also 
restore the activity of NF-kappa B, an important molecule in tumor development and, 
in turns, depends on the expression regulation of NF-kappa B (Mandal, 1996; 
Feuillard et al., 2000; Khoshnan, 2000; Crawford et ai, 2001). This fact makes Bcl-2 
a common target of chemotherapeutic agents. Fortunately, previous study shows that 
BH3-only Bcl-2 family members such as Bim has shown to interact with Bcl-2 and 
antagonize its anti-apoptotic activity (Puthalakath et al, 1999). Studies on reducing 
the activity of Bcl-2 have generated fruitful results on chemotherapeutic agent 
development. 
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1.7.2. Nuclear factor kappa B 
Nuclear factor kappa B (NF-kappa B) is a redox-sensitive transcription factor. This 
ubiquitous molecule is regulated by many apoptotic stimuli or inhibitors. Standing in 
the center of many cellular response and stimulation, NF-kappa B serves as an 
important regulator of stress response, cell adhesion and proliferation (Pahl, 1999). 
NF-kappa B is a common name for the product of gene NF-kB-Rel family (Perkins, 
2004). Up to five subunits of the NF-kappa B complex have been identified in 
mammalian cells including RelA(p65), RelB, c-Rel, pl05-p50, lytlO. All five 
subunits contain Rel homology domain at the N-termini which facilitates 
DNA-binding and dimerization to form homodimers or heterodimers (Perkins 1997; 
Ghosh et al, 1998; Perkins, 2000). Normally, inactive NF-kappa B subunits are 
bound to members of inducible kappa B (I-kappa B) family: I-kappa a, p and 8 
(Ghosh et al, 1998，Perkins, 2000). In response to inflammatory cytokines, 
activation of I-kappa B kinase (IKK) is promoted and phosphorylates members of 
I-kappa B which result in degradation by proteosomes (Ghosh et al” 2002). 
NF-kappa B that is bounded to I-kappa B is then released and translocated into the 
nucleus where it regulates transcription of genes. NF-kappa B plays an important role 
in the immune response, inflammatory response and, last but not least, regulation of 
2 5 
apoptosis (Gerondarkis et al” 1999; Pahl, 1999). In terms of regulation of apoptosis, 
the importance of NF-kappa B is shown by study Gerondarkis et al. that RelA(p65) 
knockout mice died in utero as a result of TNF-a induced apoptosis in hepatocytes 
(Gerondarkins et al, 1999). The most important mechanism of NF-kappa B in 
promoting tumorigenesis is its ability to up-regulate the expression of anti-apoptotic 
genes such as Bcl-2 and Bcl-xL (Barkett et al , 1999; Feuillard et al., 2000; Tamatani 
et al, 2000; Kurland, 2001; Kirito et al., 2002). Inhibition of NF-kappa B is shown to 
down-regulate anti-apoptotic members of the Bcl-2 family, which, as a result, leads 
to apoptosis. Moreover, NF-Kappa B promotes the transcription of Bcl-2 and Bcl-xL 
genes by binding to the promoter region of these two genes (Feuillard et al., 2000; 
Khoshnan, 2000; Kurland, 2001). Bcl-2, on the other hand, is able to positively 
feedback to stimulate or restore the activity of NF-kappa B (Mandal, 1996; Crawford 
et al., 2001). The above features of NF-kappa B clearly state that targeting NF-kappa 
B is an important direction of novel chemotherapeutic agent development. 
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1.7.3. Inducible nitric oxide synthase 
Inducible nitric oxide synthase (iNOS) exerts effects to cells by production of nitric 
oxide (NO) in cells and creating NO-mediated stress in cells. NO exists in cells as a 
radical. NO is known as a component related to inflammation in the past (Kroncke et 
al., 1991). In the advance of molecular knowledge, NO apparently plays a role in 
apoptosis by production of NO in the tumor microenviroment (Kroncke et al., 2001). 
However, apoptotic ability of NO is not uni-directional, but either served as a tumor 
suppressor or promoter in different situations has been described in different studies 
(Lechner, 2005). Subjected to factors like concentration of NO produced, cell type, 
environment stress, etc., NO has pivotal actions in cells (Kroncke et al” 2001). Low 
concentrations of NO have been reported to increase the resistance of cells to 
apoptosis (Mannick et al., 1994; Genaro et al, 1995; Tzeng et al. 1998; Kroncke et 
al” 2001). At high concentrations, NO induces cell death via either necrosis or 
apoptosis, depending on cell type (Fehsel et al, 1994; Ha & Snyder, 1999; Zhou et 
al., 2000). Subjected to the energy level of cells, NO induces cell death by necrosis 
via energy depletion or, otherwise, apoptosis (Ha & Snyder, 1999). In apoptotic 
models, NO can upset the balance between pro- and anti-apoptotic molecules in cells 
and shift the effect to either direction (Ushmorov et al., 1999，Kroncke et al, 2001). 
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NO has been shown to be cytoprotective in hepatocytes and prevents cell death at 
low NO concentrations (Kim et al., 1997; Tzeng et al., 1998; Mojena et al., 2001). 
Inhibition of iNOS, on the other hand, reduces lung injury in a number of animal 
models (Haddad, 1994; Kooy, 1995; Hierholzer et al., 1998; Mikawa et al., 1998). 
But the action of NO in these two cell types is not limited to the patterns above. 
Addition of carbon monoxide results in a reciprocal effect on the pivotal action of 
NO in both lung and liver cells in vivo (Sarady et al., 2004). Such an action of NO 
which leads to either side of cell death creates both opportunity and difficulties to 
therapeutic implementation of iNOS derived NO in cancer therapy. 
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1.8. Side-effects of chemotherapy 
Chemotherapy usually affects all internal organs. Regardless to somatic cells or 
cancer cells, chemotherapeutic agents lead to unpredictable damages, or side-effects, 
either reversible of irreversible to the function of the affected organ. Side-effects 
often deteriorate normal function of organs which may be lethal to individuals. 
Chemotherapy is always strictly monitored to avoid or minimize the occurrence of 
side-effects. Prescription of chemotherapeutic agents to patients from clinicians is 
based on the inherent premise that the drug benefits on anti-cancer effect. But the 
margin for benefit and risk may narrow in some cases. Chemotherapeutic drugs may 
result in side effects such as liver dysfunction or nephrotoxicity, which, in turn, 
increases the toxic effect of the chemotherapeutic agents (Field & Michael, 2008). In 
general, liver dysfunction leads to the reduced ability of the liver to metabolize, 
uptake, and excretion of chemotherapeutic agents. This will either prolonged drug 
toxicity in the body, or reduced activation of pro-drugs (Field & Michael, 2008). 
Nephrotoxicity, which leads to acute renal failure, will lead to the high mortality rate 
(Caglar et al” 2002). Urea, a major metabolic waste, accumulates in body and 
develops toxicity to somatic cells. The failure of either liver or kidney can be 
life-threatening and therefore strict monitoring on the effect on chemotherapeutic 
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agents on the two organs is absolutely necessary in novel drug development. 
1.8,1, Chemotherapy and liver dysfunction 
Liver is the chemical plant of the body. Major biochemical reactions take place in 
liver, including metabolism, catabolism, detoxification, etc. Liver plays an important 
role in drug metabolism, where it breaks down drugs and aids the excretion of the 
drug out of body or activates pro-drug to unleash the therapeutic ability of the drug 
(Gamucio & Chianale，1968). Thus monitoring on the damage on liver by the action 
of the chemotherapeutic agents is necessary. Moreover, monitoring the status of liver 
will aids in the progression of the disease and the response to therapeutic intervention 
(McFarlane & Bomford，2008). In common practices, the aminotransferases are 
widely used as a marker for hepatocyte disruption (Clermont & Chalmers，1967). 
These aminotransferases catalyse the transfer of an a-amino acid to and a-oxo acid 
(Bomford & McFarlane, 2008). These functions are all intracellular functions and do 
not take place in plasma. The elevation of these intracellular aminotransferases thus 
indicates the damage on hepatocytes. Two aminotransferases are widely measured as 
indicators: aspartate aminotransferase (AST, or previously known as glutamate 
oxaloacetate transaminase, GOT) and alanine aminotransferase (ALT, or previously 
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known as glutamate pyruvate transaminase, GPT). In general practices, a major, ten 
times or above, increase in the plasma concentration than the reference range are 
specifically associated with primary hepatocyte damage (McFarland & Bomford, 
2008). AST and ALT plasma concentrations below 10 times of the upper reference 
range value are often treated as non-specific interference as both enzymes have wide 
tissue distribution. Thus a major elevation in the plasma concentration will be 
confident in reflecting the hepatocyte damage induced by the chemotherapeutic 
agents. 
1.8.2. Nephrotoxicity of chemotherapeutic agents 
The kidneys are responsible to excrete waste products and toxins from the body in 
forms of urine. Kidneys filter blood to produce glomerular filtrate, reabsorb 
important solvent and solute such as water, glucose electrolytes, etc. back to the 
circulation system, and remain metabolic waste and toxins in urine which finally 
released from body (Kon & Marshall，2008). Failure in proper functioning of the 
kidneys results in accumulation of metabolic waste and toxin in the body, disordered 
electrolytes homoeostasis, and disturbances of extracellular fluid composition. All 
these effects can be life-threatening (Kon & Marshall, 2008). The effects of the 
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chemotherapeutic agents on the kidney functions are critical in studies of novel 
chemotherapeutic agents (Weiss & Poster�1982). Two major analyses are widely 
employed in renal function tests, creatinine and urea (Carmicheal et al, 1990). The 
creatinine is a normal metabolic product of muscle which is produced in a constant 
rate daily. Creatinine is excreted by glomerular filtration and is a good marker to 
monitor the glomerular filtration rate which is directly related to the renal function 
(Kon & Marshall�2008). The measurement of creatinine can be done via creatinine 
clearance in urine or the plasma creatinine concentration. Another major marker for 
the renal function is the plasma urea. But the use of plasma urea alone is affected by 
several disadvantages. Urea is an end product of metabolism of nitrogenous 
substance in the body. These nitrogenous substances are mainly amino acids. The 
urea is freely filtrated by the kidneys. However, the plasma concentration is related 
on the production in liver. Combined liver and renal failure can result in normal 
plasma urea concentration (Kon and Marshall, 2008). But the disadvantage can be 
removed by comparing the result with the plasma creatinine concentration. Thus 
coupling the two measurements can confidently reflect the renal function under 
chemotherapy. 
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1.9. Aim of study 
The aim of this study is to analyze 5F as a chemotherapeutic agent in mouse. In the 
previous studies, there was enough evidence that supported 5F as an effective 
anti-tumor agent. As the first in vivo study of 5F, we are putting the focus on 1) the 
chemotherapeutic effect of 5F in vivo; 2) the possibility of difference in the 
therapeutic effects of 5F between two different types of cancers; 3) whether the 
mechanisms of 5F-induced apoptosis parallel with our previous in vitro studies; and 
4) analysis any possible side effects of 5F. 
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Chapter 2: Materials and 
Methodology 
2.1. Animals 
2.1,1, HCC model 
Male C3H/HeJ mice were used as in vivo model to study anti-tumor effect of 5F 
against HCC. Infant C3H/HeJ mice aged about four to six days are received with 
lactating Institute for Cancer Research mice (ICR mice) as nursery. Every five to six 
infant received was allocated with one nursery. Liver carcinogen diethylnitrosamine 
(DEN) or saline as control was injected into mice at 12 days (See section 2.2.1 for 
details). Observation on the condition of the nursery was taken twice a day to ensure 
the nursery did not assault the juveniles. Nurseries were removed at 22-26 day, 
depending on the ability of the C3H/HeJ mice to intake solid diet and/or lactating 
ability of the nurseries, and sacrificed by cervical dislocation. The C3H/HeJ mice 
were divided into groups and continue on treatment study (See 2.4 for details). 
Animals were weighted every two weeks to ensure 5F did not have lethal 
toxicological effect on the mice. Mouse individuals that have a decrease of body 
weight to twenty-five percent of mean starting body weight of whole population was 
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euthanized. On the day after end of treatment, mice were anaesthetized by 0.07ml of 
solution made by a mixture of 10% ketamine (Alfasan, Holland) and 2% Xylazine 
(Alfasan, Holland) at a proportion of 50:50. After harvest of samples and tissues, all 
mice were scarified by cervical dislocation after dissection of tissues. 
2-1.2. Lung cancer model 
Male A/J mice were used as in vivo model of lung cancer. Young mice at four weeks 
old were received in batches of six to fifteen. The mice were allowed to grow to six 
weeks old. Lung carcinogen was injected into mice at age of six weeks old (See 
section 2.2.2 for details). The A/J mice were divided into groups and continue on 
treatment study (See section 2.4 for details). Animals were weighted every two 
weeks to ensure 5F did not have lethal toxicological effect on the mice. Mouse 
individuals that have a decrease of body weight to twenty-five percent of mean 
starting body weight of whole population was euthanized. On the day after the end of 
treatment, mice were anaesthetized by 0.05ml of solution made by a mixture of 10% 
ketamine (Alfasan, Woerden, Holland) and 2% Xylazine (Alfasan, Woerden, Holland) 
at a proportion of 50:50. After blood sampling and tissue harvesting, all mice were 
scarified by cervical dislocation. 
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All mice were obtained from Laboratory Animal Service Center (LASEC), The 
Chinese University of Hong Kong. Dry pellet diet and water were given ad libitum. 
The animals were kept under constant, specific pathogen free condition, with 
artificial light cycle from 7 am to 9 pm. Handling, maintenance, treatment and 
sacrifice of animals were conducted in LASEC Research Unit at Prince of Wales 
Hospital, in accordance to US guidelines (NIH publication no. 85-23) and were 
approved by both university ethics committee and Hong Kong Special 
Administrative Region Government. 
2.2. Tumors induction 
2.2.1, HCC induction in C3H/HeJ mice 
Diethylnitrosamine (DEN) was used to induce HCC in C3H/HeJ mice. The 
administration of DEN to C3H/HeJ mice followed Li's publication (Li et al” 1991). 
At the age of 12 days, C3H/HeJ mice were administrated with a single dose of 
carcinogen DEN (Sigma-aldrich, St. Louis, MO). The administration was done via 
intra-peritoneal injection (i.p.). The working DEN 0.1% solution, prepared by 
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diluting 1% DEN solution with normal saline, was injected once intto 12-day-old 
juveniles of C3H/HeJ mice at a dose of 20|ig/g body weight. After the administration 
of DEN, the tumor was allowed to develop for 17 weeks. Body weight of individual 
mouse was recorded every other week as a possible index to monitor the growth of 
tumor, as the growth of tumor may be proportional to the body weight (Shiota et ai, 
1999). At the first day of week, mice were assigned into groups and treatment of 
5F was commenced. 
2,2,2. Lung cancer induction in A/J mice 
4-(N-methyl-N-nitrosamino)-1 -(3-pyridyl)-1 -butanone (NNK) was administratered 
as lung carcinogen. The administration method was adapted from Belinsky's method 
(Belinsky et al, 1992). Lung carcinoma was induced by administration of a single 
dose of NNK (Chemsyn Science Laboratories, Lenexa, KS) to A/J mice of six week 
old. The administration was lOOmg/kg of NNK via i.p. to A/J mice. Lung tumors 
were allowed to develop for 18 weeks before 5F treatment. The weight measurement 
of individual mouse was done every two weeks. After 18 weeks, A/J mice were 
assigned in to groups and started receiving treatment. 
3 7 
2.3. 5F preparation 
5F extracts were obtained from Institute of Biochemistry and Molecular Biology, 
Guangdong Medical College, Guangdong, People's Republic of China. 5F was 
extracted from PsL by alcohol-extraction (Li et al., 1999). The purity of 5F was 
determined by spectrophotometry, following the protocol in Li's study (Li et al, 
1999). 5F extract was received in the form of yellowish powder. A total of 3 batches 
of 5F were received. The purity of each batch of 5F was measured by Guangdong 
Medical College and was labeled along with the container. Standardized working 
solutions of 5F were prepared by dissolving weighed extract powders to phosphate 
buffered saline (PBS) to a final concentration of 7.2 mg/mL. The solutions were 
adjusted to pH 9.5 in the aid of magnetic stirring until the extract was completely 
dissolved. To facilitate injection into mice, the solution was re-adjusted to pH 7.5. 
The re-adjustment was done gradually to prevent formation of coarse precipitates 
which may precipitate out 5F from solution. After pH adjustment, the solution was 
allowed to stir for 60 minutes at room temperature. All working solutions were 
disinfected by passing through 0.22|xm syringe filters in prior to administration and 
were stored in sterile containers at 4°C. All 5F solutions were not stored for more 
than 3 days. Solutions with visible crystallization observed were immediately 
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discarded. Aliquots of the working solution from different batches of 5F extract 
powder were tested with culture of HepG2 cells to ensure the ability of the working 
solution in inducing apoptosis. 
2.4. 5F treatment 
Mice in both models were divided into 13 groups (Table. lA: liver cancer, Table IB: 
lung cancer). Each group of mice contains 8-12 mice. The working 5F solution was 
administered via i.p. at designated concentrations. Treatment of 5F was given 5 days 
per week. 5-Fluorouracil (5-FU) was administered parallel of 5F to Group 4-7 at the 
start of treatment as positive treatment controls. 30mg of 5-FU (Sigma-aldrich, St. 
Louis, MO) was dissolved in 1 ml of culture grade DMSO. Dissolved 5-FU was 
diluted with 22^m-filtered PBS to a final volume of 10ml, at a concentration of 
3mg/ml. 5-FU was administrated to mice via i.p. at 30mg/kg for 5 days at the start of 
the treatment (Beverly et al, 2000). PBS was administered via i.p. as vehicle in 
Group 8 and 12. The whole treatment lasted for 12 weeks for HCC model and 18 
weeks for lung cancer model. Mice were sacrificed on the next day after treatment 
ended (See section 2.5 for details). 
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Table lA. Mouse groups and the treatment (liver cancer) 
Group 1 DEN^-5F12mgAg 
Group 2 DEN-»-5F24mgAg 
Group 3 DEN+5F48mgAg 
Group 4 DEN+5F 12mg/kg +5-FU 
Group 5 DEN+5F24meAe +5-FU 
Group 6 DEN<-5F48mg/kg +5-FU 
Group 7 DEN+5-FU 
Group 8 DEN 
Group 9 Salinc+5F12mg/kg 
Group 10 Salinc+5F24mg/kg 
Group 11 Salinc+5F48mg/kg 
Group 12 Saline (VchicIc) 
Group 13 Salinc+5-FU 
5F: oncc doily for 5 days following a 2-ddv breok. TrcolmciU iosis for 12 
weeks 
5-FU: BOmg/kfi daily for 5 d.iys 
Table IB. Mouse groups and the treatment (lung cancer) 
Group 1 NNK+5F12mgAg 
Group 2 NNK+-5F24mg/kg 
Group 3 NNK+5F48mg/kg 
Group 4 NNK-»-5F12mgAg +5-FU 
Group 5 NNK+5F24mg/kg +5-FU 
Group 6 NNK+5F48mg/kg +5-FU 
Group 7 NNK+5-FU 
Group 8 NNK 
Group 9 Sallnc+5F12mg/kg 
Group 10 Salinc+5F24mg/kg 
Group 11 Salino+5F48mg/kg 
Group 12 Saline (VchicIc) 
Group 13 Salinc+5-FU 
5F: oncc doily for 5 days following a 2-day break. Treatment lasts for 18 
weeks 
5-FU: 30mg/kR ddily for 5 days 
Table 1: Group distribution and treatment of mice. 
5F was given in 3 concentrations (12mg/kg, 24mg/kg, 48mg/kg) in combination of 
test (Group 1-3), positive control (Group 4-6), negative control (Group 9-11) 
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2.5. Harvest of samples and tissues 
On the day after the treatment period, all mice were anaesthetized by protocols 
mentioned in the "Animal model" section. The blood of mice was drawn by direct 
venal puncture at the posterior vena cava. Whole liver, lungs, spleen and kidneys in 
all mice were dissected and weighted. Liver of C3H/HeJ mouse and lungs of A/J 
mouse were shown in Figure 6. Left lobes of liver tissues of C3H/HeJ mice, and the 
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right lung of the A/J mice were formalin fixed while the rest of the tissue was rapidly 
frozen in liquid nitrogen for protein, RNA and DNA extraction in future studies. The 
left lope of liver fixed with 10% buffered formalin directly in the C3H/HeJ mice 
model. The right lung of the A/J mice was perfused with 0.4 ml of 10% buffered 
formalin from the bronchia and was then fixed in 10% buffered formalin. All 
formalin fixed tissues were examined after overnight fixation and all surface lesions 
were counted and record. In liver tissues, lesions with diameter greater than 3 mm, 
between 1-3 mm, and below 1 mm were counted separately. Number of lung lesions 
was counted directly. Formalin-fixed left lobes and right lung were cut into 4 equal 
pieces after tumor count and were fixed in new 10% buffer formalin for an extra of 
48 hours. Tissue processing was taken after tissues were fixed for a total of 72 hours 
and processed tissues were embedded with paraffin wax. Paraffin wax embedded 
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tissues were sectioned by Leica Rotary Microtome RM2135 (Leica Microsystems, 
Wetzlar, Germany) to 4|xm thick sections and sections were mounted on pre-cleaned 
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Figure 6: Tissues of liver (C3H/HeJ) and lung (A/J). C3H/HeJ mouse liver with 
HCC (Above, Left) and a normal mouse liver (Above, Right). Lung of A/J mouse 
showing lung adenocarcinoma (Below, Left) and normal lung of A/J mouse (Below, 
Right) 
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2.6. Tumor assessment 
Sections from the two models were stained with haematoxylene & eosin stain (H&E). 
Slides with section mounted were processed with xylene to dissolve the paraffin wax. 
De-paraffinnized slides were allowed to hydrate by passing through series of 
downgrading ethanol. Hydrated slides were stained with Harris haematoxylene 
(Vector Labs., Burlingame, CA) solution for 3 minutes. After rinsing with tap water, 
slides were immersed in Scott's tap water for 1 minute to allow color consolidation, 
followed by differentiation with 2% acid alcohol for 10 seconds. The haematoxylene 
stained slides were counter stained by eosin stain for 1 minute. The slides were than 
allow to wash in running tap water until no more stain diffused from section. Slides 
were dehydrated by upgrading alcohol and xylene, then mounted permanently under 
glass slides with DPX mountant. Mountant of slides were allowed to dry overnight in 
fume hood. The slides were observed under Zeiss Axioplan 2 imaging microscope 
(Carl Zeiss Microimaging GmbH, Gottengen, Gemany). Microscopic images in this 
study were visualized and captured by SPOT Software 4.7 (Diagnostic Instruments 
Inc., Sterling Heights, MI). 
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The total number of solid tumors in 4 separate sections was counted under light 
microscopy. Counting of tumors was done at low power field of 50x magnification. 
Tumors were counted separately into three categories according to their sizes: less 
than 1mm in diameter, 1 to 3 mm in diameter, and over 3 mm in diameter. In 
calculation of the tumor volume, the category of less than 1mm in diameter was 
calculated as 1mm, 1 to 3mm diameters calculated as 2mm, and over 3mm diameters 
calculated as 3mm, respectively. The total volume of all visible tumors in one 
individual was calculated by a formula: volume = n7cd/2 (Carlsson et al., 1983). All 
tumor volume data were rounded up to 2 decimal places. The mean volume within 
each group was calculated for statistical comparison. 
2.7. Investigation of apoptosis and 
cell proliferation 
The occurrence of apoptosis in-vivo was assessed by TdT-mediated dUTP-X nick 
end labeling (TUNEL) assay. Slides with mounted sections were processed with 
hydration with series of down-grading ethanol. The hydrated slides were immersed 
in a lOmM citrate buffer. Antigens in situ were heat-retrieved using domestic 
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microwave oven for 20 minutes and were allowed to cool down slowly to room 
temperature. After washes of PBS for three times, In Situ Cell Death Detection Kit 
(Roche Applied Science, Indianapolis, IN) was applied to sections according to the 
instruction by the manufacturer. Stained slides were mounted with 20|il of ProLong® 
Gold Antifade Reagent (Invitrogen Corporation, Carlsbad, CA) under pre-cleaned 
glass cover slips. The antifadin agent was allowed to dry dark room overnight. 
Stained sections were observed under fluorescence microscope and imaged by Zeiss 
Imaging System. 
Cell proliferation was determined by detecting proliferative cell nuclear antigen 
(PCNA) in-situ using avidin-biotin complex (ABC) immunohistochemical technique. 
Sections from both models were mounted on microscopic slides and were 
de-parafFiimized using xylene. The de-paraffinnized slides were hydrated by series of 
down-grading ethanol. Epitopes of PCNA were heat-retrieved using lOmM citrate 
buffer in domestic microwave device for 20 minutes. All slides were washed twice in 
distilled water for two minutes and treated with 3% hydrogen peroxide for 5 minutes. 
After washed three times with PBS, horse serum horse serum was applied to sections 
for 30 minutes to maintain equilibrium environment in situ. 
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In HCC model, mouse-monoclonal PCNA antibody (Santa Cruz Biotechnology, 
SC-25280, Santa Cruz, CA) at 1:300 was used as primary antibody along with a 
Mouse-on-mouse Immunodetection Kit (Vector Labs., Burlingame, CA) according to 
manufacturer's instruction. After washing 3 times with PBS for 5 minutes, PCNA 
antibody-tagged sections were visualized by 3,3'-diaminobenzidine (DAB) substrate 
kit (Vector Labs., Burlingame, CA). 
In lung cancer model, the level of PCNA was detected by adding 30|il 
rabbit-monoclonal anti-mice PCNA antibody (Abeam Inc., ab2426, Cambridge, MA) 
at diluted in horse serum in a dilution of 1:1000 as primary antibody with an 
incubation time of two hours thirty minutes at room temperature. The slides were 
then washed with PBS two minutes for twice. 3 drops of Immpress anti-rabbit kit 
(Vector Labs., Burlingame, CA) was used as anti-rabbit secondary antibody and ABC 
signal amplification. The slides were incubated for thirty minutes and washed with 
PBS for 5 minutes. The PCNA signals were visualized by DAB-peroxidase kit 
(Vector Labs., Burlingame, CA). 
After color depositing by DAB in both models, the slides were counterstained with 
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Mayer's haematoxylene (Vector Labs., Burlingame, CA) for 3 seconds and 
differentiate in running water until no more stains came out from sections. The slides 
were then dehydrated and mounted under pre-cleaned glass cover slips using DPX 
mountant. The signals of PCNA were observed and captured using Zeiss Imaging 
System. 
2.8. Immunohistochemistry 
Levels of apoptotic signaling molecules were detected by means of 
immunohistochemistry in situ. Sections were mounted on frosted microscopic slides. 
The slides were de-paraffmnised and hydrated by xylene and down-grading ethanol. 
Epitopes in situ were retrieved by heating slides for 20 minutes in domestic 
microwave device. All slides were washed twice in distilled water for two minutes 
and treated with 3% hydrogen peroxide for 5 minutes. Horse serum was added to the 
section and incubated for thirty minutes to maintain equilibrium of environment in 
situ. lOO i^l (in HCC model)/40^1 (in lung cancer model) of rabbit-polyclonal 
anti-mouse Bcl-2 (Santa Cruz Biotechnology, sc-492, Santa Cruz, CA), 
rabbit-polyclonal anti-mouse Bax (Santa Cruz Biotechnology, sc-526) in dilution of 
1:200，rabbit-polyclonal anti-mouse Bak (Santa Cruz Biotechnology, sc-832) in 
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dilution of 1:100，mouse-polyclonal NF-kappa B p65 (in HCC model) (Santa Cruz 
technology, sc-8008) in dilution of 1:40 together with Mouse-on-mouse 
Immunodetection kit (Vector Labs), rabbit-polyclonal anti-mouse NF-kappa B p65 
(in lung cancer model) (Santa Cruz Biotechnology, sc-372) in dilution of 1:100， 
rabbit-polyclonal anti-mouse iNOS (Thermo Fisher/Lab Vision, Fremont, CA) in 
dilution of 1:100，rabbit-polyclonal anti-mouse I-kappa B alpha (Abeam Inc., 
ab47752, Cambridge, MA) in dilution of 1:100，and rabbit-polyclonal anti-mouse 
Erkl/2 (Cell Signaling Technology, #4695, Danvers, MA) in dilution of 1:200 were 
employed as primary antibodies. All antibodies, except NF-kappa B p65 (Santa Cruz 
Biotechnology, sc-8008) were diluted in horse serum according to dilution stated 
above. Incubation condition for all antibodies was two hours thirty minutes in room 
temperature, except Erkl/2 (Cell Signaling Technology, #4695) in 4 � C overnight. 
After incubation of primary antibodies, the slides were washed twice in PBS for two 
minutes. 3 drops of Immpress anti-rabbit kit (Vector Labs.) was then applied as 
anti-rabbit secondary antibody and ABC amplification of signals. Signals were 
visualized by staining with DAB substrate kit (Vector Labs.). Slides were washed for 
five minutes in running water and counterstained by Mayer's haematoxylene (Vector 
Labs.). All slides were dehydrated by upgrading ethanol and xylene. Dehydrated 
slides were mounted under pre-cleaned glass cover slips with DPX mountant. All 
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slides were observed under Zeiss Imaging System (Carl Zeiss Microimaging GmbH) 
and captured by SPOT software (Diagnostic Instrument Inc.). All slides were viewed 
by blind investigator and the result was recorded according to a detailed scoring 
system (Table 2). 
4 9 
Table 2. Grading Criteria for Immunohistochemical Staining 
Score 1: Less than 10% of cells were positive with the respective antibody in 20 
random high power field. 
Score 2: 10%-30% of cells were positive with the respective antibody in 20 random 
high power field. 
Score 3: 30%-50% of cells were positive with the respective antibody in 20 random 
high power field. 
Score 4: More than 50% of cells were positive with the respective antibody in 20 
random high power field. 
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2.9. Biochemical test 
Mouse serum was tested for the parameters on aspartate aminotransferrase (AST), 
alanine aminotransferrase (ALT), serum creatinine level (CRE), blood urea nitrogen 
(BUN) index to determine effect of 5F on liver function, reflected by AST and ALT 
level, and renal function, reflected by CRE and BUN, as a preliminary screening of 
side-effects. Blood samples of all mice were obtained by direct venal puncture at 
posterior vena cava. All samples were collected into labeled 1.7ml microcentrifuge 
tubes and were allowed to clot for fifteen minutes at room temperature. Serum of the 
blood samples were separated by centrifugation of the clotted blood at a speed of 
3000 rpm at room temperature. Serum separated was transferred to labeled sterile 
microcentrifuge tubes and was stored at -80°C. Before the measurement of 
biochemical parameters, the serum was thawed in 37°C water bath. 
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2.9,1. Liver Function Tests (LFT) 
2.9.1.1. Aspartate aminotransferase (AST) & Alanine 
aminotransferase (ALT) 
The activity of AST and ALT were measured by means of enzyme-substrate kinetic 
assay. The terminal mice sera stored in -80°C were thawed at 37°C in water bath just 
before the analysis. lO i^l of serum was added into 8-well ELISA strip. Aliquots of 
two reaction solutions from AST In Vitro Diagnostic Kit and ALT In Vitro Diagnostic 
Kit (King Hawk Pharmaceutics Co. Ltd., Beijing, PRC), named R1 and R2 by the 
manufacturer, was pre-heated in the 37°C water bath. 2 0 0 o f pre-heated solution 
R1 and 50|il of R2 was added into serum containing ELISA strip wells. The solutions 
were mix well by vortex and incubated at 37°C for one minute. The absorbance of 
the solution was recorded by automated spectrophotometer at time intervals of 0, 15, 
30，45 and 60 seconds, using primary wavelength of 340nm, reference wavelength of 
450nm and negative growth rate as reaction type, as instructed by the manufacturer. 
The AST and ALT concentration was calculated by the following formula: 
AST or ALT (U/L) = AA/min x 6547.5 
6547.5 was a constant supplied by the manufacturer. The reference range of the AST 
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and ALT in mice is similar to most mammals, including human. The reference ranges 
of AST and ALT used for this study were: AST < 37U/L and ALT < 40U/L (Jacob et 
al.’ 2002). 
2.9,2. Renal Function Test (RFT) 
2.9.2.1. Serum creatinine level (CRE) 
The serum creatinine level was measured by picric acid assay. 8|il of thawed serum 
was added to a 8-well ELISA strip. Creatinine In Vitro Diagnostic Kit was used to 
detect the serum creatinine (King Hawk, Beijing, PRC). 240 i^l of reagent R1 was 
added to the serum and was allowed to incubate at 37°C for one minute. After 
incubation, the absorbance was read. The absorbance of the signal was recorded by 
automatic spectrophotometer at primary wavelength of 546 nm, reference 
wavelength at 700 nm and terminal positive reaction as reaction type. 80|xl of R2 was 
added to the mixture and incubate further for 5 minutes at 37°C. The absorbance was 
read after the 5' incubation. A standard solution, supplied by the manufacturer, was 
applied instead of the sample as standard in each lot. The concentration of the 
creatinine in serum was calculated by following formula: 
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CRE (nmol/L) = ASample/AStandard x 442.0 
442.0 is a concentration of the standard supplied by the manufacturer. Reference 
range for CRE in mice, which is similar to human, is <106|imol/L (Jacob et al” 
2002). 
2.9.2.2. Blood Urea Nitrogen index (BUN) 
The blood urea nitrogen (BUN) concentration was measured by two point 
glutamatdehydrogenase (GLDH) method. 3|il of mice serum was added to 8-well 
ELISA strip. BUN In Vitro Diagnostic Kit was applied in this study (King Hawk, 
Beijing, PRC). 240^1 of R1 and 60^1 of R2 was added to the serum and vortex well. 
The mixture was incubated at 37°C for one minute. The absorbance at this time point 
was taken using primary wavelength of 340 nm, reference wavelength of 405 nm, 
reaction type as two-point negative growth reaction. The second absorbance was 
taken after further incubation of 100 seconds. The BUN concentration wa calculated 
by the following formula: 
BUN (mmol/L) = ASample/AStandard x 8.34 
8.34 is the concentration for the standard which is supplied by the manufacturer. The 
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BUN concentration in mice, which is similar to human, has a reference range of 
1.8-7.1 mmol/L and panic concentration of >35.7mmol/L. 
2.10. Statistical analysis 
The number of animals used for each group is indicated in the results section. The 
data are expressed as mean 士 SD. Comparisons of terminal weights, tumor count, 
total tumor volume, and biochemical tests between test treatment groups and no 
treatment group (Group 1-7 against Group 8; Group 9-11, 13 against Group 12) were 
performed by unpaired Student /-test. Comparisons of TUNEL score, PCNA index, 
all immunohistochemical staining scores between test treatment groups and no 
treatment group (Group 1-7 against Group 8; Group 9-11, 13 against Group 12), test 
treatment groups and positive control groups (Group 1-6 against Group 7), negative 
control groups and vehicle receiving group (Group 9-11，13 against Group 12), test 
treatment and respective positive and negative controls in same concentration given 
(Group 1，2，3 against Group 4, 5, 6，and Group 9，10, 11，respectively) were 
performed by Mann-Whitney U test. Statistical significance was considered at 
P<0.05. 
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Chapter 3: Results 
3.1. Anti-tumor effect of 5F is dose-
dependent 
To examine the tumorcidal effect 5F is effective against HCC tumors and lung 
tumors, the total number of tumors in liver or lung (Fig. 7A, HCC model; Fig 7B, 
lung cancer model) was counted to calculate the total volume of tumors using the 
formula described in the section of Methods (Fig 8A, HCC model; Fig 8B, lung 
cancer model). The result showed that total tumor volume of all 5F treatment groups 
(Group 1-3) is lower than the non-treatment control (Group 8) in both models. In 
terms of the tumor number, 5F significantly reduced the number of larger tumors 
(>lmm in diameter) in the 48mg/kg treatment (Group 3，P<0.05) as well as the 
number of smaller tumors (<lmm in diameter) in 12mg/kg (Group 1，P<0.05), 
24mg/kg (Group 2,户<0.05)，12mg/kg plus 5-FU (Group 4，户<0.05) and 24mg/kg 
plus 5-FU (Group 5,户<0.05) in HCC model. In lung cancer model, 5F reduced the 
number of tumors significantly in mice receiving 24mg/kg (Group 2, P<0.05), 
48mg/kg (Group 3，P<0.05), 12mg/kg plus 5-FU (Group 4，户<0.05) and 24mg/kg 
plus 5-FU (Group 5,户<0.05). This indicates that 5F alone is able to reduce the total 
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tumor number of HCC and lung carcinoma. It was also noted that the higher the dose 
of 5F, the greater the tumorcidal effect. The total volume was decreased against the 
concentration of 5F (Group 1-3). Among all groups, mice receiving 24mg/kg (Group 
2), 48mg/kg (Group 3) 5F treatment had significantly lower in total tumor volume 
when compared with non-treatment group (Group 8) (P<0.05). However, the 
significant difference was not seen between Group 1 (12mg/kg) and Group 8 
(non-treatment control). 5F in combination with 5-FU were also effective at low 
concentration of 5F. Groups receiving 5F at a concentration of 12mg/kg plus 5-FU 
(Group 4)，24mg/kg plus 5-FU (Group 5) significantly reduced the total tumor 
volume (P<0.05). 
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Fig. 7A Tumor count (HCC) 
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Figure 7A: The number of tumors in liver. DEN was given to mice to induce liver 
tumor. 17 weeks after DEN treatment, mice were treated with 5F, 5-FU and both in 
combination for 12 weeks. At the end of treatment, livers were collected and stained 
with H&E. The number of tumors was counted. *Significant difference compared 
with Group 8 (尸<0.05). 
Fig. 7B Tumor Count (Lung Cancer) 
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Figure 7B: The number of tumor in lungs. NNK was given to mice to induce lung 
tumor. 18 weeks after NNK treatment, mice were treated with 5F, 5-FU and both in 
combination for 18 weeks. At the end of treatment, Lungs were collected and stained 
with H&E. The number of tumors was counted. *Significant difference compared 
with Group 8 (P<0.05). 
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Fig. 8A Volume of HCC tumors 
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Figure 8A: The volume of liver tumors. DEN was given to mice to induce liver 
tumor. 17 weeks after DEN treatment, mice were treated with 5F, 5-FU and both in 
combination for 12 weeks. At the end of treatment, livers were collected and stained 
with H&E. The number of the tumor was counted and the total volume of tumors 
was calculated by formula: v = imd/2. *Significant difference compared with Group 
8 (P<0.05). 
Fig. 8B Volume of lung tumors 
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Figure 8B: The volume of lung tumors. NNK was given to mice to induce lung 
tumor. 18 weeks after NNK treatment, mice were treated with 5F, 5-FU and both in 
combination for 18 weeks. At the end of treatment, lungs were collected stained with 
H&E. The total volume was calculated by formula: v = rmdJl. *Significant difference 
compared with group 8 (P<0.05). 
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3-2. 5F reduces cell proliferation and 
induces apoptosis in-vivo 
PCNA index in situ was measured to determine the level of cell proliferation in liver 
and lung. A trend of decreasing PCNA index was seen in Group 1-3 of both models 
(Fig. 9A & 10，HCC model; Fig. 9B & 11，lung cancer model). Individual 
comparison of the PCNA index of 5F treatment groups (Group 1-6) with the control 
non-treatment group was done to investigate the therapeutic effectiveness of 5F. 
Proliferation of cells was significantly reduced in 12mg/kg (Group 1)，24mg/kg 
(Group 2), and 48mg/kg (Group 3) when compared to the non-treatment group 
(Group 8) (P<0.05) in HCC model. In lung cancer model, the PCNA index was 
reduced in all 5F-receiving groups (Group 1-6) when compared with non-treatment 
group (Group 8) (P<0.05) These results showed that 5F was able to inhibit cell 
proliferation in a dose-dependent manner. 
To assess the occurrence of apoptosis in vivo of the animals, in situ TUNEL assay on 
tissue sections was used to quantify level of cell death on the sample (Fig. 12A & 13， 
HCC model; Fig. 12B & 14, lung cancer model). TUNEL assay indicates 5F had 
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successfully induced apoptosis in vivo. In all 5F-treated groups (Group 1-7) in both 
models, TUNEL scores were significantly higher than Group 8 in both models 
(P<0.05). This indicates that 5F-induced apoptosis occurred in vivo. Moreover, 
scoring of the TUNEL assay in samples of Group 1-3 increased with the 
concentration of 5F received in both models. This observation was supported by the 
increase in the TUNEL scoring in 5F-treated tumor-free mice (Group 9-11). Thus 
apoptosis induced by 5F was dose-dependent. In HCC model, the TUNEL score of 
24mg/kg (Group2) and 48mg/kg (Group 3) is significantly higher when compared to 
the positive control 5-FU (Group 7) as well as the respective 5F plus 5-FU groups 
(Group 5, 6)(户<0.05). This showed that 5F at 24mg/kg or higher concentrations 
could significantly induce apoptosis. In lung cancer model, 5F had a similar 
anti-tumor effect, but the significant effect even extended to the lower concentration 
of 5F 12mg/kg (Group 1) when compared with the 12mg/kg plus 5-FU (Group 4). 
These results indicate that the anti-tumor effect of 5F is associated with apoptosis in 
a dose-dependent manner. 
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Fig. 9A The level of PCNA in liver 
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Figure 9A: The level of PCNA in mouse liver. DEN was given to mice to induce 
liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 5-FU and 
both in combination for 12 weeks. At the end of treatment, livers were collected for 
immunohistochemical staining for PCNA. Detailed group information was shown in 
Table lA. The intensity was scored according to Table 2. *Significant difference 
compared with group 8 (P<0.05). ^Significant difference between combined 
treatment (Group 1 and 4，2 and 5, 3 and 6) (P<0.05). 
Fig.9B The level of PCNA in lung 
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Figure 9B: The level of PCNA in mouse lung. NNK was given to mice to induce 
liver tumor. 18 weeks after NNK treatment, mice were treated with 5F, 5-FU and 
both in combination for 18 weeks. At the end of treatment, lungs were collected for 
immunohistochemical staining of PCNA. Detailed group information in was shown 
Table IB. The intensity was scored according to Table 2. •Significant difference 
compared with group 8 (尸<0.05). ^Significant difference between combined 
treatment (Group 1 and 4，2 and 5，3 and 6)(尸<0.05). 
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Figure 10: Immunohistochemical staining of PCNA in the liver tissues of HCC 
model. DEN was given to mice to induce liver tumor. 17 weeks after DEN treatment, 
mice were treated with 5F, 5-FU and both in combination for 12 weeks. At the end of 
treatment, livers were collected for immunohistochemical staining of PCNA. From 
left to right, above to below: DEN + 12mg/kg (Group 1), DEN + 24mg/kg (Group 2), 
DEN + 48mg/kg (Group 3)，DEN + 12mg/kg + 5-FU (Group 4)，DEN + 24mg/kg + 
5-FU (Group 5)，DEN + 48mg/kg + 5-FU (Group 6), DEN + 5-FU (Group 7)，DEN 
only (Group 8) and vehicle (Group 12). Detailed grouping information was shown in 
Table lA. 
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Figure 11: Immunohistochemical staining of PCNA in lung tissues of the lung 
cancer model. NNK was given to mice to induce liver tumor. 18 weeks after NNK 
treatment, mice were treated with 5F, 5-FU and both in combination for 18 weeks. At 
the end of treatment, lungs were collected for immunohistochemical staining of 
PCNA. From left to right, above to below: NNK + 12mg/kg (Group 1)，NNK + 
24mg/kg (Group 2)，NNK + 48mg/kg (Group 3)，NNK + 12mg/kg + 5-FU (Group 4)， 
NNK + 24mg/kg + 5-FU (Group 5), NNK + 48mg/kg + 5-FU (Group 6), NNK + 
5-FU (Group 7)，NNK only (Group 8) and vehicle (Group 12).. Detailed grouping 
information was shown in Table IB. 
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Fig. 12A TUNELindex in liver 
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Figure 12A: TUNEL index in mouse liver tissues. DEN was given to mice to 
induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 5-FU 
and both in combination for 12 weeks. At the end of treatment, livers were collected 
for TUNEL staining. Detailed group information was shown in Table lA. The 
intensity of the staining was scored according to Table 2. *Significant difference 
compared with group 8 (P<0.05). ^Significant difference between 5F-treated mice 
and 5F plus 5-FU-treated mice (Group 1 and 4, 2 and 5, 3 and 6) (P<0.05). 
Fig. IIB TUNEL index in lung 
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Figure 12B: TUNEL index in mouse lung tissues. NNK was given to mice to 
induce liver tumor. 18 weeks after NNK treatment, mice were treated with 5F, 5-FU 
and both in combination for 18 weeks. At the end of treatment, lungs were collected 
for TUNEL staining. Detailed group information was shown in Table IB.The 
intensity of the staining was scored according to Table 2. *Significant difference 
compared with group 8 (P<0.05). ^Significant difference between 5F-treated mice 
and 5F plus 5-FU-treated mice (Group 1 and 4，2 and 5, 3 and 6)(尸<0.05). 
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Figure 13: Representative TUNEL staining of liver tissues. DEN was given to 
mice to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 
5-FU and both in combination for 12 weeks. At the end of treatment, livers were 
collected for TUNEL staining. From left to right, above to below: DEN + 12mg/kg 
(Group 1)，DEN + 24mg/kg (Group 2), DEN + 48mg/kg (Group 3)，DEN + 12mg/kg 
+ 5-FU (Group 4)，DEN + 24mg/kg + 5-FU (Group 5), DEN + 48mg/kg + 5-FU 
(Group 6)，DEN + 5-FU (Group 7), DEN only (Group 8) and vehicle (Group 12). 
Detailed grouping information was shown in Table 1 A. 
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Figure 14: Representative TUNEL staining of lung tissues. NNK was given to 
mice to induce liver tumor. 18 weeks after NNK treatment, mice were treated with 5F, 
5-FU and both in combination for 18 weeks. At the end of treatment, lungs were 
collected for TUNEL staining. From left to right, above to below: NNK + 12mg/kg 
(Group 1), NNK + 24mg/kg (Group 2), NNK + 48mg/kg (Group 3)，NNK + 
12mg/kg + 5-FU (Group 4), NNK + 24mg/kg + 5-FU (Group 5)，NNK + 48mg/kg + 
5-FU (Group 6), NNK + 5-FU (Group 7), NNK only (Group 8) and vehicle (Group 
12). Detailed grouping information was shown in Table IB. 
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3.3. Effects of 5F on apoptotic 
signaling molecules 
3,3.1. 5F up-regulates pro-apoptotic Bax and Bak 
In situ Bax and Bak were assessed by immunohistochemicai technique. Levels of 
Bax and Bak were quantified by a pre-determined scoring scale system. In general, 
5F up-regulated Bax and Bak in a dose-dependent manner. The expression scores of 
Bax on sections increased with the concentration of 5F given (Fig. 15A, HCC model; 
Fig. 15B, lung cancer model), from a mean of 2.2 in 12mg/kg group (HCC model, 
Group 1) to mean of 3.9 in 48mg/kg group (HCC model, Group 3) and 2.4 in 
12mg/kg group (Lung cancer model, Group 1) to 4.0 in 48mg/kg group (Lung cancer 
model, Group 3). This observation was supported by a similar trend in the 5F-treated 
non-tumor-bearing mice in both models (Groups 9-11). Thus, the effect of 5F in 
up-regulating Bax can be positively associated to the concentration given. 
Comparing to the tumor-bearing non-treatment group (Group 8), all 5F receiving 
groups (Group 1-6) had a significant increase in Bax signals in situ in both models 
(P<0.05). In both models, mice receiving 48mg/kg 5F treatment were significantly 
higher in the level of Bax, when compared to the 5-FU positive control (Group 7， 
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户<0.05) and the 5-FU combination (Group 6，P<0.05). This reflects that 5F at the 
highest concentration given in this study is most effective in raising pro-apoptotic 
Bax levels in vivo, which further supports the observation of dose-dependent effect 
of5F. 
In both models the regulation of Bak by 5F was in general similar to Bax. A trend of 
dose-dependent effect was also observed in 5F-tested groups of both models (Group 
1-3) and supported by similar trends in respective 5F-treated non-tumor-bearing mice 
(Group 9-11) (Fig. 18A, HCC model; Fig. 18B, lung cancer model). The mean score 
of Bak in mice treated with 12mg/kg was 2.5 (HCC model, Group 1) and 2.2 (Lung 
cancer model, Group 1) while in mice treated with 48mg/kg was 3.0 (HCC model, 
Group 3) and 3.2 (Lung cancer model, Group 3). The increase in the expression of 
Bak can be related to the dose of 5F given. Comparing to the tumor-bearing 
non-treatment group (Group 8)，a significant raise in the Bak level was observed in 
5F-receiving groups (Group 1-6) in both models (P<0.05). However, when 
comparing to the effects with the 5-FU combination groups, significant difference 
was found in mice treated with 24mg/kg (Group 2) as well as in mice treated with 
48mg/kg (Group 3) in lung cancer model (户<0.05). In HCC model, only 48mg/kg 
(Group 3) had such significant observation (P<0.05). This indicates that 5F could 
up-regulate Bak in lung cancer cells more effectively than in HCC cells. 
6 9 
Fig. ISA Bax level in liver tissues 
4 - * X J 
I： III II l i l l l i l 
1 2 3 4 5 6 7 8 9 1 0 11 12 1 3 
Group 
Figure 15A: The expression of Bax in mouse liver tissues. DEN was given to mice 
to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 
5-FU and both in combination for 12 weeks. At the end of treatment, livers were 
collected for immunohistochemical staining of Bax. Detailed group information was 
shown in Table lA.The intensity of staining was scored according to Table 2. 
•Significant difference compared with group 8 (P<0.05). '^Significant difference 
between 5F-treated mice and 5F plus 5-FU-treated mic (Group 1 and 4, 2 and 5, 3 
and 6)(尸 <0.05). 
Fig. 15B Bax level in lung tissues 
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Figure 15B: The expression of Bax in mouse lung tissues. NNK was given to mice 
to induce liver tumor. 18 weeks after NNK treatment, mice were treated with 5F, 
5-FU and both in combination for 18 weeks. At the end of treatment, lungs were 
collected for immunohistochemical staining of Bax. Detailed group information was 
shown in Table IB.The intensity of staining was scored according to Table 2. 
•Significant difference compared with group 8 (P<0.05). ^Significant difference 
between 5F-treated mice and 5F plus 5-FU-treated mice (Group 1 and 4，2 and 5, 3 
and 6)(尸<0.05). 
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Figure 16: Immunohistochemical staining of Bax in the liver of HCC model. 
DEN was given to mice to induce liver tumor. 17 weeks after DEN treatment, mice 
were treated with 5F, 5-FU and both in combination for 12 weeks. At the end of 
treatment, livers were collected for immunohistochemical staining of Bax. From left 
to right, above to below: DEN + 12mg/kg (Group 1)，DEN + 24mg/kg (Group 2), 
DEN + 48mg/kg (Group 3)，DEN + 12mg/kg + 5-FU (Group 4)，DEN + 24mg/kg + 
5-FU (Group 5)，DEN + 48mg/kg + 5-FU (Group 6), DEN + 5-FU (Group 7), DEN 
only (Group 8) and vehicle (Group 12).. Detailed grouping information was shown in 
Table lA. 
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Figure 17: Immunohistochemical staining of Bax in mouse lung tissues. NNK 
was given to mice to induce liver tumor. 18 weeks after NNK treatment, mice were 
treated with 5F, 5-FU and both in combination for 18 weeks. At the end of treatment, 
lungs were collected for immunohistochemical staining of Bax. From left to right, 
above to below: NNK + 12mg/kg (Group 1)，NNK + 24mg/kg (Group 2), NNK + 
48mg/kg (Group 3)，NNK + 12mg/kg + 5-FU (Group 4), NNK + 24mg/kg + 5-FU 
(Group 5), NNK + 48mg/kg + 5-FU (Group 6), NNK + 5-FU (Group 7)，NNK only 
(Group 8) and vehicle (Group 12). Detailed grouping information was shown in 
Table IB. 
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Figure 18A: The expression of Bak in mouse liver tissues. DEN was given to mice 
to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 
5-FU and both in combination for 12 weeks. At the end of treatment, livers were 
collected for immunohistochemical staining of Bak. Detailed group information was 
shown in Table lA.The intensity of staining was scored according to Table 2. 
*Significant difference compared with group 8 (P<0.05). ^Significant difference 
between 5F-treated mice and 5F plus 5-FU-treated mice (Group 1 and 4, 2 and 5, 3 
and 6) (P<0.05). 
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Figure 18B: The expression of Bak in mouse lung tissues. NNK was given to mice 
to induce liver tumor. 18 weeks after NNK treatment, mice were treated with 5F, 
5-FU and both in combination for 18 weeks. At the end of treatment, lungs were 
collected for immunohistochemical staining of Bak. Detailed group information was 
shown in Table IB.The intensity was scored according to Table 2. *Significant 
difference compared with group 8 (P<0.05). ^Significant difference between 
5F-treated mice and 5F plus 5-FU-treated mice (Group 1 and 4，2 and 5, 3 and 6) 
(P<0.05). 
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Figure 19: Immunohistochemicai staining of Bak in liver tissues. DEN was given 
to mice to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 
5F, 5-FU and both in combination for 12 weeks. At the end of treatment, livers were 
collected for immunohistochemicai staining of Bak. From left to right, above to 
below: DEN + 12mg/kg (Group 1)，DEN + 24mg/kg (Group 2), DEN + 48mg/kg 
(Group 3)，DEN + 12mg/kg + 5-FU (Group 4)，DEN + 24mg/kg + 5-FU (Group 5), 
DEN + 48mg/kg + 5-FU (Group 6)，DEN + 5-FU (Group 7)，DEN only (Group 8) 
and vehicle (Group 12). Detailed grouping information was shown in Table 1 A. 
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Figure 20: Immunohistochemical staining of Bak in lung tissues. NNK was given 
to mice to induce liver tumor. 18 weeks after NNK treatment, mice were treated with 
5F, 5-FU and both in combination for 18 weeks. At the end of treatment, lungs were 
collected for immunohistochemical staining of Bak. From left to right, above to 
below: NNK + 12mg/kg (Group 1)，NNK + 24mg/kg (Group 2), NNK + 48mg/kg 
(Group 3)，NNK + 12mg/kg + 5-FU (Group 4)，NNK + 24mg/kg + 5-FU (Group 5), 
NNK + 48mg/kg + 5-FU (Group 6), NNK + 5-FU (Group 7)，NNK only (Group 8) 
and vehicle (Group 12).. Detailed grouping information was shown in Table IB. 
7 5 
3.3.2. 5F down-regulates anti-apoptotic 
NF-kappa B and Bcl-2 
Regulation on anti-apoptotic molecules was also observed in mice treated with 5F. 
L 
NF-kappa B and Bcl-2, both generally known as anti-apoptotic signaling molecules, 
were down-regulated by treatment of 5F. NF-kappa B and Bcl-2 expression was 
assessed by immunohistochemistry. Assessment of the level of expression was 
quantified by means of scoring system described in the previous chapter. The scoring 
of NF-kappa B in situ showed that NF-kappa B was down-regulated by 5F in general 
(Fig. 21A & 22, HCC model; Fig. 21B & 23, lung cancer model). A decreasing trend 
of NF-kappa against the concentration of 5F given was observed. From mice treated 
with 12mg/kg scoring of 2.1 (HCC model, Group 1) and 2.9 (Lung cancer model, 
Group 1) to mice treated with 48mg/kg scoring 1.2 (HCC model, Group 3) and 1.1 
(Lung cancer model, Group 3)，a down-regulation against the 5F concentration was 
observed. The down-regulation trend was supported by up-regulation of I-kappa B a 
in mice treated with 5F (Fig. 24A & 25，HCC model; Fig. 24B & 26, lung cancer 
model). This indicated that the high level of I-kappa B would prevent NF-kappa B 
from releasing from its complex of I-kappaB and NF-kappa-B and thus keep 
NF-kappaB inactive. The suppression of the phosphorylation of I-kappa B thus can 
7 6 
be associated with the apoptotic action of 5F. This suppression is also related to the 
concentration of 5F. By comparing with the tumor-bearing non-treatment group 
(Group 8)，all 5F-receiving groups in both models (Group 1-6) showed a 
significantly lower level of NF-kappa B (P<0.05), which is supported by the 
significant increase in scoring of I-kappa B a (P<0.05). This result indicated that 5F 
can down-regulate NF-kappa B in vivo. Moreover, the level of NF-kappaB in the 
48mg/kg group (Group 3) was significantly different from the positive control 
(Group 7，P<0.05) and the 5-FU combination treatment group (Group 6，P<0.05). 
This finding further supports the dose-dependent effect of 5F in down-regulation of 
the NF-kappa B. 
The expression of Bcl-2 in all groups is similar to that of the NF-kappa B. The 
decreasing trend against the concentration was also observed in both models (Fig. 
27A, HCC model; Fig. 27B, lung cancer model). The expression scoring of Bcl-2 
decreased from 1.8 (HCC model) and 2.7 (Lung cancer model) in mice treated with 
12mg/kg (Group 1) to 1.6 (HCC model) and 1.5 (Lung cancer model) in mice treated 
with 48mg/kg 5F (Group 3). The result showed that the decrease in the expression of 
Bcl-2 is proportional to the concentration of 5F. The levels of Bcl-2 in all 
5F-receiving groups (Group 1-6) were significantly lower than the tumor-bearing 
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non-treatment group (Group 8，P<0.05) in both models. The effect of 5F between the 
two models, however, is slightly different. In the lung cancer model, the significant 
decrease of Bcl-2 was found between the mice treated with 24mg/kg (Group 2， 
P<0.05), 48mg/kg (Group 3，P<0.05) and the mice treated with the respective 5F 
and 5-FU in combination (Group 5 & 6) but not in the mice treated with 12mg/kg 
(Group 1) and its corresponding group receiving 5F and 5-FU in combination (Group 
4). In the HCC model, on the other hand, there was significant difference between 
mice treated with 12 mg/kg (Group 1) or with 24 mg/kg (Group 2) and their 
corresponding groups receiving 5F and 5-FU in combination (Group 4 or Group 5) 
(both 尸<0.05). It is noticeable that the dose-dependent effect of 5F was only 
observed in the lung cancer model but not in the HCC model. Since 5F in all three 
doses had a similar degree of effect on the expression of Bcl-2 in the HCC mouse 
model, it is possible that a dose-dependent curve may be feasible if the low doses of 
5F is used. 
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Figure 21A: The level of NF-kappa B (p65) in liver tissues of HCC mouse model. 
den was given to mice to induce liver tumor. 17 weeks after DEN treatment, mice 
were treated with 5F, 5-FU and both in combination for 12 weeks. At the end of 
treatment, livers were collected for immunohistochemical staining of NF-kappa B. 
Detailed group information was shown in Table lA. The intensity of the staining was 
scored according to Table 2. *Significant difference compared with group 8 (P<0.05). 
^Significant difference between combined treatment (Group 1 and 4，2 and 5，3 and 6) 
(P<0.05). 
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Figure 2IB: The level of NF-kappa B (p65) in liver tissues of lung cancer mouse 
model. NNK was given to mice to induce liver tumor. 18 weeks after NNK treatment, 
mice were treated with 5F, 5-FU and both in combination for 18 weeks. At the end of 
treatment, lungs were collected for immunohistochemical staining of NF-kappa B. 
Detailed group information was shown in Table IB.The intensity was scored 
according to Table 2. *Significant difference compared with group 8 (尸<0.05). 
八Significant difference between combined treatment (Group 1 and 4’ 2 and 5，3 and 6) 
(P<0.05). 
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Figure 22: Immunohistochemical staining of NF-kappa B (p65) in the liver 
tissues of HCC mouse model. DEN was given to mice to induce liver tumor. 17 
weeks after DEN treatment, mice were treated with 5F, 5-FU and both in 
combination for 12 weeks. At the end of treatment, livers were collected for 
immunohistochemical staining of NF-kappa B. From left to right, above to below: 
DEN + 12mg/kg (Group 1)，DEN + 24mg/kg (Group 2), DEN + 48mg/kg (Group 3)， 
DEN + 12mg/kg + 5-FU (Group 4), DEN + 24mg/kg + 5-FU (Group 5)，DEN + 
48mg/kg + 5-FU (Group 6)，DEN + 5-FU (Group 7), DEN only (Group 8) and 
vehicle (Group 12). Detailed grouping information was shown in Table 1 A. 
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Figure 23: Immunohistochemical staining of NF-kappa B (p65) in lung tissues in 
lung cancer mouse model. NNK was given to mice to induce liver tumor. 18 weeks 
after NNK treatment, mice were treated with 5F, 5-FU and both in combination for 
18 weeks. At the end of treatment, lungs were collected for immunohistochemical 
staining for NF-kappa B. From left to right, above to below: NNK + 12mg/kg (Group 
1)，NNK + 24mg/kg (Group 2), NNK + 48mg/kg (Group 3)，NNK + 12mg/kg + 
5-FU (Group 4)，NNK + 24mg/kg + 5-FU (Group 5), NNK + 48mg/kg + 5-FU 
(Group 6)，NNK + 5-FU (Group 7)，NNK only (Group 8) and vehicle (Group 12). 
Detailed grouping information was shown in Table IB. 
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Figure 24A: The level of I-kappa B a in liver tissues of HCC mouse model. DEN 
was given to mice to induce liver tumor. 17 weeks after DEN treatment, mice were 
treated with 5F, 5-FU and both in combination for 12 weeks. At the end of treatment, 
livers were collected for immunohistochemical staining for I-kappa B a. Detailed 
group information in Table lA.The intensity was scored according to Table 2. 
•Significant difference compared with group 8 (P<0.05). ^Significant difference 
between combined treatment (Group 1 and 4，2 and 5, 3 and 6)(户<0.05). 
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Figure 24B: The level of I-kappa B a in lung tissues of lung cancer mouse model. 
NNK was given to mice to induce liver tumor. 18 weeks after NNK treatment, mice 
were treated with 5F, 5-FU and both in combination for 18 weeks. At the end of 
treatment, lungs were collected for immunohistochemical staining of I-kappa B a. 
Detailed group information was shown in Table IB.The intensity was scored 
according to Table 2. *Significant difference compared with group 8 (P<0.05). 
八Significant difference between combined treatment (Group 1 and 4，2 and 5, 3 and 6) 
(P<0.05). 
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Figure 25: Immunohistochemical staining of I-kappa B a in liver tissues in HCC 
mouse model. DEN was given to mice to induce liver tumor. 17 weeks after DEN 
treatment, mice were treated with 5F, 5-FU and both in combination for 12 weeks. 
At the end of treatment, livers were collected for immunohistochemical staining of 
I-kappa B a. From left to right, above to below: DEN + 12mg/kg (Group 1)，DEN + 
24mg/kg (Group 2)，DEN + 48mg/kg (Group 3), DEN + 12mg/kg + 5-FU (Group 4)， 
DEN + 24mg/kg + 5-FU (Group 5), DEN + 48mg/kg + 5-FU (Group 6)，DEN + 
5-FU (Group 7), DEN only (Group 8) and vehicle (Group 12). Detailed grouping 
information was shown in Table 1 A. 
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Figure 26: Immunohistochemical staining of I-kappa B a in lung tissues in lung 
cancer mouse model. NNK was given to mice to induce liver tumor. 18 weeks after 
NNK treatment, mice were treated with 5F, 5-FU and both in combination for 18 
weeks. At the end of treatment, lungs were collected for immunohistochemical 
staining of I-kappa B a. From left to right, above to below: NNK + 12mg/kg (Group 
1), NNK + 24mg/kg (Group 2), NNK + 48mg/kg (Group 3), NNK + 12mg/kg + 
5-FU (Group 4)，NNK + 24mg/kg + 5-FU (Group 5)，NNK + 48mg/kg + 5-FU 
(Group 6), NNK + 5-FU (Group 7), NNK only (Group 8) and vehicle (Group 12). 
Detailed grouping information was shown in Table IB. 
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Figure 27A: The expression of Bcl-2 in mouse liver tissues. DEN was given to 
mice to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 
5-FU and both in combination for 12 weeks. At the end of treatment, livers were 
collected for immunohistochemical staining of Bcl-2. Detailed group information 
was shown in Table lA.The intensity was scored according to Table 2. *Significant 
difference compared with group 8 (P<0.05). ^Significant difference between 
combined treatment (Group 1 and 4，2 and 5, 3 and 6) (P<0.05). 
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Figure 27B: The expression of Bcl-2 in mouse lung tissues. NNK was given to 
mice to induce liver tumor. 18 weeks after NNK treatment, mice were treated with 5F, 
5-FU and both in combination for 18 weeks. At the end of treatment, lungs were 
collected for immunohistochemical staining of Bcl-2. Detailed group information 
was shown in Table IB.The intensity was scored according to Table 2. *Significant 
difference compared with group 8 (P<0.05). ^Significant difference between 
combined treatment (Group 1 and 4，2 and 5，3 and 6) (P<0.05). 
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Figure 28: Immunohistochemicai staining of Bcl-2 in liver tissues in HCC mouse 
model. DEN was given to mice to induce liver tumor. 17 weeks after DEN treatment, 
mice were treated with 5F, 5-FU and both in combination for 12 weeks. At the end of 
treatment, livers were collected for immunohistochemicai staining of Bcl-2. From 
left to right, above to below: DEN + 12mg/kg (Group 1)，DEN + 24mg/kg (Group 2), 
DEN + 48mg/kg (Group 3), DEN + 12mg/kg + 5-FU (Group 4), DEN + 24mg/kg + 
5-FU (Group 5), DEN + 48mg/kg + 5-FU (Group 6), DEN + 5-FU (Group 7)，DEN 
only (Group 8) and vehicle (Group 12). Detailed grouping information was shown in 
Table lA. 
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Figure 29: Immunohistochemical staining of Bcl-2 in lung tissues in lung cancer 
mouse model. NNK was given to mice to induce liver tumor. 18 weeks after NNK 
treatment, mice were treated with 5F, 5-FU and both in combination for 18 weeks. At 
the end of treatment, lungs were collected for immunohistochemical staining of 
Bcl-2. From left to right, above to below: NNK + 12mg/kg (Group 1), NNK + 
24mg/kg (Group 2)，NNK + 48mg/kg (Group 3)，NNK + 12mg/kg + 5-FU (Group 4)， 
NNK + 24mg/kg + 5-FU (Group 5), NNK + 48mg/kg + 5-FU (Group 6)，NNK + 
5-FU (Group 7)，NNK only (Group 8) and vehicle (Group 12). Detailed grouping 
information was shown in Table IB. 
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3.3.3. 5F up-regulated iNOS in HCC but not in 
lung cancer 
To investigate the effect of 5F on the level of iNOS, in situ iNOS level was 
visualized by immunohistochemistry. The effect of 5F on iNOS was different 
between HCC and lung cancer. In general, 5F raised the level of iNOS in liver (Fig. 
30A & 31). The expression of iNOS in HCC model increased with the concentration 
of 5F given, from a mean scoring of 2.9 in mice treated with 12mg/kg (Group 1) to 
3.6 in mice treated with 48mg/kg (Group 3). The scoring of iNOS in 5F-receiving 
groups (Group 1-6) of the HCC model was significantly higher than the score from 
tumor-bearing non-treatment group (Group 8, P>0.05). Such difference was also 
seen in the mice treated with 5F only (Group 1-3)，compared with the positive 
control group (Group 7，户<0.05). Moreover, the significant up-regulation of iNOS 
was also observed in mice treated with 48mg/kg 5F (Group 3), compared with those 
treated with 48mg/kg 5F plus 5-FU (Group 6) (P<0.05). Overall the expression 
pattern of iNOS is similar to that of pro-apoptotic molecules such as Bax and Bak. 
Since nitric oxide, the product of iNOS, is known to promote apoptosis in certain 
tumors (Fehsel et al., 1994; Ha & Snyder，1999; Zhou et al” 2000), therefore, the 
5F-induced iNOS up-regulation in this study may be regarded as being pro-apoptotic 
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in nature. However, 5F had no effect on the expression of iNOS in lung tumor tissues 
of the mouse model (Fig. 30B). iNOS activation was detected in circulatory system, 
i.e., blood vessels, in lung section, but not in surrounding lung tissues (Fig. 32). This 
indicated that 5F in blood stream was able to raise level of iNOS in vivo while lung 
epithelium resisted to such regulations. Thus effect of 5F on iNOS appears to be 
associated with apoptosis in liver tissues only. 
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Figure 30A: The level of iNOS in liver tissues of HCC mouse model. DEN was 
given to mice to induce liver tumor. 17 weeks after DEN treatment, mice were 
treated with 5F, 5-FU and both in combination for 12 weeks. At the end of treatment, 
livers were collected for immunohistochemical staining of iNOS. Detailed group 
information was shown in Table lA.The intensity was scored according to Table 2. 
*Significant difference compared with group 8 (P<0.05). ^Significant difference 
between combined treatment (Group 1 and 4, 2 and 5, 3 and 6) (P<0.05). 
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Figure 30B: The level of iNOS in lung tissues in lung cancer mouse model. NNK 
was given to mice to induce liver tumor. 18 weeks after NNK treatment, mice were 
treated with 5F, 5-FU and both in combination for 18 weeks. At the end of treatment, 
lungs were collected of immunohistochemical staining for iNOS. Detailed group 
information was shown in Table IB.The intensity was scored according to Table 2. 
•Significant difference compared with group 8 (P<0.05). ^Significant difference 
between combined treatment (Group 1 and 4，2 and 5, 3 and 6) (P<0.05). 
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Figure 31: Immunohistochemical staining of iNOS in liver tissues in HCC 
mouse model. DEN was given to mice to induce liver tumor. 17 weeks after DEN 
treatment, mice were treated with 5F, 5-FU and both in combination for 12 weeks. At 
the end of treatment, livers were collected for immunohistochemical staining of 
iNOS. From left to right, above to below: DEN + 12mg/kg (Group 1)，DEN + 
24mg/kg (Group 2), DEN + 48mg/kg (Group 3)，DEN + 12mg/kg + 5-FU (Group 4)， 
DEN + 24mg/kg + 5-FU (Group 5)，DEN + 48mg/kg + 5-FU (Group 6), DEN + 
5-FU (Group 7), DEN only (Group 8) and vehicle (Group 12). Detailed grouping 
information was shown in Table 1 A. 
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Figure 32: Immunohistochemical staining of iNOS in lung tissues in lung cancer 
mouse model. NNK was given to mice to induce liver tumor. 18 weeks after NNK 
treatment, mice were treated with 5F, 5-FU and both in combination for 18 weeks. At 
the end of treatment, livers were collected for immunohistochemical staining of 
iNOS. Picture was taken from group receiving 48mg/kg 5F treatment test group 
(Group 3). The figure shows a blood vessel intensely stained with iNOS antibody 
(Red circle), Indicating that activation of iNOS occurred in vivo. The surrounding 
lung tissues, however, did not stained with the antibody. iNOS was not activated in 
the surrounding tissue. 
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3.3.4, Regulation on Erkl/2 was associated with 
treatment of 5F 
The expression of Erkl/2 was assayed by immunohistochemical technique in situ. 
Regulation of Erkl/2 was observed in all mice treated with 5F, however, reciprocal 
result was observed between the two models. In HCC model (Figs. 33A & 34)，the 
Erkl/2 expression wass significantly higher in mice treated with 5F (Group 1-6) than 
the tumor-bearing non-treatment group (Group 8，P<0.05). Moreover, an increasing 
trend from scores of 2.3 in mice treated with 12mg/kg 5F (Group 1) to score of 3.4 in 
mice treated with 48mg/kg 5F (Group 3) was observed. However, a similar 
expression pattern was not seen in the lung cancer model (Figs. 33B & 35). In the 
lung cancer model a significant down-regulation was observed in all mice treated 
with 5F (Group 1-6) when compared with the tumor-bearing non-treatment (Group 8, 
P<0.05). Besides a decrease of the expression against the concentration of 5F given 
was also observed from score of 1.8 in mice treated with 12 mg/kg (Group 1) to 1.2 
in mice treated with 48 mg/kg (Group 3). 
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Fig. 33A Erkl/2 level in liver tissues 
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Figure 33A: The level of Erkl/2 in liver tissues of HCC mouse model. DEN was 
given to mice to induce liver tumor. 17 weeks after DEN treatment, mice were 
treated with 5F, 5-FU and both in combination for 12 weeks. At the end of treatment, 
livers were collected for immunohistochemical staining of Erkl/2. Detailed group 
information was shown in Table lA.The intensity was scored according to Table 2. 
*Significant difference compared with group 8 (P<0.05). ^Significant difference 
between combined treatment (Group 1 and 4，2 and 5，3 and 6) (P<0.05). 
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Figure 33B: The level of Erkl/2 in lung tissues of lung cancer mouse model. 
NNK was given to mice to induce liver tumor. 18 weeks after NNK treatment, mice 
were treated with 5F, 5-FU and both in combination for 18 weeks. At the end of 
treatment, lungs were collected for immunohistochemical staining of Erkl/2. 
Detailed group information was shown in Table IB.The intensity was scored 
according to Table 2. *Significant difference compared with group 8 (P<0.05). 
八Significant difference between combined treatment (Group 1 and 4, 2 and 5, 3 and 6) 
(P<0.05). 
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Figure 34: Immunohistochemical staining of Erkl/2 in liver tissues in HCC 
mouse model. DEN was given to mice to induce liver tumor. 17 weeks after DEN 
treatment, mice were treated with 5F, 5-FU and both in combination for 12 weeks. At 
the end of treatment, livers were collected for immunohistochemical staining of 
Erkl/2. From left to right, above to below: DEN + 12mg/kg (Group 1)，DEN + 
24mg/kg (Group 2)，DEN + 48mg/kg (Group 3), DEN + 12mg/kg + 5-FU (Group 4)， 
DEN + 24mg/kg + 5-FU (Group 5), DEN + 48mg/kg + 5-FU (Group 6)，DEN + 
5-FU (Group 7)，DEN only (Group 8) and vehicle (Group 12). Detailed grouping 
information was shown in Table 1 A. 
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Figure 35: Immunohistochemical staining of Erkl/2 in lung tissues in lung 
cancer mouse model. NNK was given to mice to induce liver tumor. 18 weeks after 
NNK treatment, mice were treated with 5F, 5-FU and both in combination for 18 
weeks. At the end of treatment, lungs were collected for immunohistochemical 
staining of Erkl/2. From left to right, above to below: NNK + 12mg/kg (Group 1)， 
NNK + 24mg/kg (Group 2), NNK + 48mg/kg (Group 3), NNK + 12mg/kg + 5-FU 
(Group 4), NNK + 24mg/kg + 5-FU (Group 5)，NNK + 48mg/kg + 5-FU (Group 6)， 
NNK + 5-FU (Group 7)，NNK only (Group 8) and vehicle (Group 12). Detailed 
grouping information was shown in Table IB. 
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3.4. Side-effect studies of 5F 
The investigation on the side-effects of 5F was divided into three parts: the 
physiological observations, liver function tests and renal function tests. In 
physiological observations, the terminal weight of mice and the fUr loss were 
investigated. In this study, first of all, no mice died with signs of intolerance to 5F 
such as over 25% weight loss, decrement of activity, self-isolation, self-torture, etc. 
In both HCC and lung cancer models, no significant weight loss between the 
5F-receiving groups (Group 1-6) and the non-treatment group (Group 8) was 
recorded, nor between non-tumor-bearing 5F treatment groups (Group 9-11) and 
non-tumor-bearing vehicle (Group 12). Fur loss in mice was mild (Table 3). No mice 
were suffered from major fur loss at the end of experiment. These results indicate 
that 5F did not result in major side-effects and was not toxicologically lethal in both 
liver and lung tumor models.. 
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TibleS. Fur lois in mice 
tmbnent Fur loss sctle 
HCC fTKxM (jufiQ cmosr mcxM 
Group 1 D E _ N K 母 t2mgn(g + + 
Group 2 DEN/NNK45F 24fng^ + 
Qraf» 3 DE_NK+5F Adaig/ka ++ ++ 
Qrai^  A DE_NK»€F • +• 
Group 5 DE_NK»^24fnDrkB^FLi ++ 
Group 6 DEN/NNK45F 48mgn«+5>FU ** +• 
GWLp 7 DEN/NNK45-FU + 
Gmp 6 DEN/NNKonly 0 0 
Group 9 Saline+5F12mg/Ko + + 
Group 10 SaiinB4€F24mg/kg + + 
Group 11 SallnB+5F48mg/ko + ++ 
Group 12 Saline (Vehicte) 0 0 
Group 13 Salin»»5-FU + + 
Table 3: Fur loss scale in mice. DEN or NNK was given to mice to induce liver or 
lung tumors respecctively. 17 weeks after DEN treatment or 18 weeks after NNK 
treatment, mice were treated with 5F, 5-FU and both in combination for 12 weeks 
(DEN-treated mice) or 18 weeks (NNK-treated mice). At the end of treatment, the fur 
loss of mice was assessed and graded. The grade criteria were quantified by the 
following: 
0: No visible fur loss. 
+： Fur loss observed after handling. 
++: Noticeable fur loss, localized area. 
+++: Majority skin surface visible. 
++++: Complete for loss (nude) 
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In liver function tests, aspartate aminotransferase (AST, Fig. 36A, HCC; Fig. 36B, 
lung cancer) and alanine aminotransferase (ALT, Fig. 37A, HCC; Fig. 37B, lung 
cancer) were used as biochemical markers. In the HCC model, mice-receiving 5F 
treatment, for both tumor-bearing and non-tumor-bearing (Group 1-6，Group 9-11) 
had significantly lower plasma AST and ALT activity than the respective 
non-treatment group (Group 8，Group 12). In the lung cancer model, a trend of 
raising AST and ALT was observed with the increase of 5F given, however, the 
increment was not significant when compared with the non-treatment group. 
Moreover, in both models, mean the AST and ALT plasma concentration of all 
groups were within the normal reference range. This indicates 5F did not result in 
liver dysfunction in our models. 
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Fig. 36A Level of AST in the mouse liver tumor 
model 
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Figure 36A: The concentration of serum AST in HCC model. DEN was given to 
mice to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 
5-FU and both in combination for 12 weeks. At the end of treatment, serum of mice 
was collected for AST assay. Detailed group information was shown in Table lA. 
•Significant difference when compared with Group 8 (P<0.05). ^Out of normal 
reference range (<37U/L). 
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Figure 36B: The concentration of serum AST in lung cancer model. NNK was 
given to mice to induce lung tumor. 18 weeks after NNK treatment, mice were 
treated with 5F, 5-FU and both in combination for 18 weeks. At the end of treatment, 
serum of mice was collected for AST assay. Detailed group information was shown 
in Table IB. *Significant difference when compared with Group 8 (尸<0.05). ^Out of 
normal reference range (<37U/L). 
1 0 0 
Fig. 37A Level of ALT in the mouse liver tumor 
model 
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Figure 37A: The concentration of serum AST in HCC model. DEN was given to 
mice to induce liver tumor. 17 weeks after DEN treatment, mice were treated with 5F, 
5-FU and both in combination for 12 weeks. At the end of treatment, serum of mice 
was collected for AST assay. Detailed group information was shown in Table lA. 
•Significant difference when compared between Groups 1-7 and Group 8，or 
between Group 9-11，13 and Group 12 (P<0.05). ^Out of normal reference range 
(<40U/L). 
Fig. 37B Level of ALT in mouse lung tumor 
model 
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Figure 37B: The concentration of serum AST in lung cancer model. NNK was 
given to mice to induce liver tumor. 18 weeks after NNK treatment, mice were 
treated with 5F, 5-FU and both in combination for 18 weeks. At the end of treatment, 
serum of mice was collected for AST assay. Detailed group information was shown 
in Table IB. *Significant difference when compared between Group 1-7 and Group 8， 
or between Group 9-11, 13 and Group 12 (户<0.05). ^Out of normal reference range 
(<40U/L). 
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In renal function test, serum creatinine (CRE, Fig. 38A, HCC; Fig. 38B, lung cancer) 
and blood urea nitrogen (BUN, Fig. 39A, HCC; Fig. 39B, lung cancer) was measured 
as an index to renal function. In both models, mean serum creatinine concentration of 
all groups treated with 5F were fallen in the normal range. Although there was a 
trend of increase in serum creatinine concentration, significant difference did not 
found when comparing across the concentrations, in both tumor-bearing and 
non-tumor-bearing groups (Group 1-3，Group 9-11). The level of BUN in both 
models, however, did not fall within the reference range. There was an increasing 
trend of BUN across the mice treated with 5F in both models. It was apparent that the 
increase in BUN was mild and did not cause any visible abnormality in mice since all 
mice appeared to be normal during the course of the experiment. The combination of 
5F with 5-FU may thus cause some side-effects on the renal function. Further 
experiments are needed to verify this result.. 
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Fig. 38A Level of creatinine in mouse liver 
tumor model 
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Figure 38A: The concentration of serum creatinine in HCC model. DEN was 
given to mice to induce liver tumor. 17 weeks after DEN treatment, mice were 
treated with 5F, 5-FU and both in combination for 12 weeks. At the end of treatment, 
serum of mice was collected for creatinine assay. Detailed group information was 
shown in Table lA. *Significant difference compared between Group 1-7 and Group 
8，or Group 9-11, 13 and Group 12 (P<0.05). ^Out of normal reference range (<106 
|imol/L). 
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Figure 38B: The concentration of serum creatinine in lung cancer model. NNK 
was given to mice to induce liver tumor. 18 weeks after NNK treatment, mice were 
treated with 5F, 5-FU and both in combination for 18 weeks. At the end of treatment, 
serum of mice was collected for creatinine assay. Detailed group information was 
shown in Table IB. *Significant difference compared between Group 1-7 and Group 
8，or Group 9-11, 13 and Group 12 (P<0.05). ^Out of normal reference range (<106 
|amol/L). 
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Fig. 39A Level of blood urea nitrogen in mouse 
liver tumor model 
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Figure 39A: The concentration of blood urea nitrogen (BUN) in HCC model. 
den was given to mice to induce liver tumor. 17 weeks after DEN treatment, mice 
were treated with 5F, 5-FU and both in combination for 12 weeks. At the end of 
treatment, serum of mice was collected for BUN assay. Detailed group information 
was shown in Table lA. *Significant difference compared between Group 1-7 and 
Group 8，or Group 9-11, 13 and Group 12 (P<0.05). ^Out of normal reference range 
(1.8-7.1mmol/L).#Out of panic range (>35.7 mmol/L). 
Fig. 39B Level of blood urea nitrogen in mouse 
lung tumor model 
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Figure 39B: The concentration of blood urea nitrogen (BUN) in lung cancer 
model. NNK was given to mice to induce liver tumor. 18 weeks after NNK treatment, 
mice were treated with 5F, 5-FU and both in combination for 18 weeks. At the end of 
treatment, serum of mice was collected for BUN assay. Detailed group information 
was shown in Table IB. *Significant difference compared between Group 1-7 and 
Group 8, or Group 9-11，13 and Group 12 (户<0.05). ^Out of normal reference range 
(1.8-7.1 mmol/L).#Out of panic range (>35.7 mmol/L). 
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Chapter 4: Discussion 
5F has been known to induce cell death in several types of tumor cells (Zhang, 1997; 
Li, 1999; Zhang, 1999; Wang, 2002; Liu, 2004; Liu, 2005; Chen, 2005). Yet in vivo 
studies of 5F have not been investigated before. Moreover, the mechanisms of 5F 
reported in different cell lines were different. In general, apoptosis induced by 5F is 
via a mitochondrial-mediated pathway. This study examined the expression of 
several apoptotic molecules in both mouse liver and lung tumor models treated by 5F 
and a number of similarities in signaling molecules regulated by 5F were found by 
comparing with the previous studies. Targeting those similarities, combination 
treatment with other anti-cancer agents can be designated in the future that may 
magnify the effectiveness of 5F. Therefore, this study may help to improve the effect 
of 5F in vivo. 
In this study, a number of molecules related to the apoptotic signaling pathways was 
found to be altered in both models of HCC and lung carcinoma. Bax and Bak were 
increased by 5F in both models. It is widely known that Bax and Bak activation is 
associated with the mitochondrial-mediated apoptosis (Gross, 1998). Bax and Bak 
are ubiquitous molecules that exist normally in the cytosol. Upon activation, the 
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cytosol Bax and Bak are translocated to the membrane of the mitochondria. After 
homo-dimerization between Bax or Bak molecules and it opens the channel entitled 
permeability transition pore (PTP) (Zoratti and Szabo, 1995; Zamzami et al, 1998). 
PTP permits mass exchange of solute across the cytosol and mitochondrial matrix. 
Opening of PTP by Bax and Bak leads to mitochondrial depolarization, and finally, 
swelling of mitochondria (Shimizu et al, 1998). Release of mitochondrial cyto c 
triggers the downstream apoptotic program (Gross, 1998). In previous study, 
5F-induced cell death is associated with activation of Bax in a p53-depentant manner 
in gastric cancer cells (Liu, 2005). In this previous study, Bax was up-regulated in 
three types of cells treated with 5F. Thus Bax and Bak activation is a major event in 
5F-induced apoptosis, though the role of Bak is on supportive role of Bax (Gross, 
1998). Further investigation is needed to explore how 5F activates Bax and Bak 
expression in the mouse liver and lung tumor models. 
NF-kappa B, standing on the crossroad of major anti-apoptotic signaling mechanisms, 
has been studied extensively as a target of novel chemotherapy agents. In 
mitochondrial-mediated apoptosis, NF-kappa B binds to the promoter region of Bcl-2 
and controls its expression (Feuillard, 2000; Kurland, 2001). On the other hand, 
Bcl-2 is able to restore the activity of NF-kappa B to enhance cell survival (Mandal, 
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1996). Previous study on the effect of NF-kappa B and Bcl-2 showed that 
over-expression of Bcl-2 will hindered the effect of 5F-induced apoptosis via 
NF-kappa B pathway (Liu, 2005). In this study, it is interesting that 5F 
down-regulated the expression of both NF-kappa B (p65) and Bcl-2 in a 
dose-dependent way. When referring to the scoring trend of both molecules, 
NF-kappa B reduction in response to the increment of 5F concentrations is more 
significant. The comparison between the test and the combination therapy showed 
that NF-kappa B suppression was significantly seen in mice treated with 24mg/kg, 5F, 
but the level of Bcl-2 was reduced in mice treated with the highest concentration of 
48mg/k 5Fg. This finding showed that 5F may regulate the expression of NF-kappa 
B-Bcl-2., Further it supports that the over-expression of Bcl-2 could be regulated by 
the level of NF-kappa B. This will help in finding combination therapy agents that 
enhance the effects of 5F on reducing NF-kappa B. 
iNOS regulates apoptosis via production and accumulation of NO inside cells 
(Kroncke et al, 2001). Endogenous NO induces apoptosis by DNA and nuclear 
fragmentation, cell shrinkage, membrane blebbing, formation of apoptotic bodies, 
caspase cascade activation, up-regulation of Fas and inhibiting expression of some 
inhibitors of apoptosis (Albina, 1993; Kwak, 2000). Reciprocal effects of NO in 
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apoptosis in liver cells and lung cells had been reported in previous literatures (Kim 
et al., 1997; Tzeng et al , 1998; Mojena et al., 2001; Haddad, 1994; Kooy, 1995; 
Hierholzer et al., 1998; Mikawa et al , 1998). iNOS at a low constitutive level has 
shown anti-apoptotic properties in tumor necrosis factor a/p (TNFayp)-mediated cell 
death (Tzeng, 1998). In this study, 5F enhanced the expression of iNOS, which may 
be pro-apoptotic in nature in liver. A similar result was previously reported in colon 
cancer cells in vitro (Chen, 2004). However, 5F was not able to increase iNOS level 
in lung in this study. Thus 5F-induced iNOS expression may probably be cell type 
specific. Further investigation should examine how 5F increases iNOS level in 
mouse liver tumor model, 
The liver is the center of all biochemical reactions of the body. The assessment of 
effects of chemotherapeutic agents on the damage to the liver is important to 
investigate the safety of the agent. In the side-effect study, it was demonstrated that 
5F did not produce significant side-effects on the liver metabolism, which was 
reflected by serum levels of AST and ALT. AST and ALT are the well-known 
markers for the liver functions, indicating the damage level of the hepatocytes 
(Clermont & Chalmers, 1967). It is understood that these two markers may not be 
able to represent the full function of liver, as the full liver function test should 
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contain a series of biochemical markers that reflects different aspects of the liver's 
daily function, including albumin, bilirubin, gamma-glytamyl transpeptidase (GGT), 
etc (Clermont & Chalmers, 1967). However, these two markers are simple to use and 
can reflect the general condition of the liver (Field & Michael, 2008). In both liver 
tumor and lung tumor models, 5F treatment did not increase the level of either AST 
or ALT, compared with the non-treated control (Group 8). However, additional liver 
function tests may be needed to examine the all possible side effects caused by 5F or 
5-FU 
The kidneys are responsible to excrete waste products and toxins from the body in 
forms of urine. Damages to the kidney will result in accumulation of wastes and 
toxins in the body which may be lethal. This made the assessment of renal damage 
critical in the development of novel chemotherapeutical agents. In this study, serum 
creatinine and BUN were employed as the marker of the renal damage. The result 
showed that 5F caused a raise in BUN, which indicates the actual damage on kidney. 
However, the result was not accompanied with the high serum creatinine 
concentration to draw a conclusion that 5F resulted in side-effects in the kidneys. In a 
full panel of renal function tests, a creatinine clearance test using the 24-hour urine is 
important. However, the 24 hour-collection of urine is difficult in sampling. The test 
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on the renal function thus limited to serum creatinine and BUN. The two indices 
subjects to metabolic variation when either one was assessed as renal function. But 
the variation of metabolism was eliminated by coupling the two (Kon & Marshall, 
2008). The renal function test in this study showed that 5F may cause the actual renal 
damage. However, the test in this study focus on the excretion function of the kidney 
and left the reabsorption function of kidney behind. These tests include the blood 
glucose and the electrolytes which are the major substance the kidneys reabsorb back 
into the body. The completion of these tests will reflect the function of the kidneys in 
detail. 
In this study, there are two unsolved observations. Erkl/2 demonstrated reciprocal 
expression and activation in the presence of 5F. In previous report, Erkl/2 is served 
as survival factors that counteract apoptosis induced by 5F (Liu et a!., 2005). In this 
study, the expression pattern of Erkl/2 follows the pattern of Bax and Bak in the 
HCC model, but follows the pattern of NF-kappa B and Bcl-2 in the lung cancer 
model. This result may indicate that the activation and regulation of Erkl/2 to be 
effected by 5F, but cannot confidently determine the function of Erkl/2 since Erkl/2 
contributes to both pro-apoptotic and anti-apoptotic functions (Ramos, 2008). Further 
investigation on the role of Erkl/2 in 5F-induced apoptosis using Erkl/2 knockout 
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mice will help to clarify the action of Erkl/2. 
Another unsolved observation is the addition of 5-FU did not enhance the effect of 
5F at high concentrations. The reason cannot be confirmed in this study. In trial study 
on combination of 5F with 5-FU on HepG2 cells revealed that expected enhancing 
effect was not detected in vitro (data not shown). Thus the possibility of 
physiological deterioration of mice by the action of 5-FU that affects the absorption 
of 5F is low. The result of 5F and 5-FU will limit the possible combination 5F with 
other chemotherapeutic agent in the future and thus critical for the implementation of 
5F into further trials. 
Drug metabolism is one of the most important topics in the process of drug 
development. The possibility of a drug that may be metabolized by enzymes inside 
body, which are mainly contributed by the liver, will determine the way by which the 
drug is taken and distribute inside the body (Zhang et al, 2008). A drug can either be 
a pro-drug which will be activated after liver metabolism, or naturally process 
therapeutic effect (Zhang & Can., 2008). Thus the liver metabolism can be beneficial 
or destructive to drugs. An orally administrated drug faces one more challenge 
besides of the liver metabolism. Upon reaching the stomach, the drug must be able to 
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withstand strong acid condition in prior to arriving and being absorbed by the 
intestine (Grossman, 2008). After passing the check points of acidic condition of the 
stomach and metabolism of the liver, the drug will be transported to the rest of the 
body by various vehicles according to the hydrophobic or hydrophilic nature of the 
drug. Hydrophobic drugs mostly bind to lipoproteins in the blood stream, while 
hydrophilic drugs mostly bind to albumin (Xia et al., 2008). On reaching cells, 
hydrophobic drugs can pass through cell membrane directly while hydrophilic drugs 
have to pass through channels to reach the cytosol in order to take effect. Some drugs 
may omit the entering of the cell membrane by activating the cell receptors on the 
cell surface. Mainstream chemotherapeutic agents are mostly designed to be orally 
taken. This will provide easier treatment administration and management to both 
patients as well as physicians. In this study, 5F was given to mice via intra-peritoneal 
injection which is similar to venal injection in human. This is crucial that the drug 
can reach tissues at the native form, without liver metabolism and acidic reaction. 5F 
working solution was prepared by dissolving the extract in presence of alkali 
condition, followed by re-adjustment of the solution to neutral condition before 
administering to the animal. This indicates that 5F in solution will be subjected to 
changes in stomach if 5F is orally administrated. The aim of this study was to 
confirm the apoptotic ability of 5F in vivo. Any possible changes to the conformation 
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of 5F will lead to variation of the results or even appearance of false 
positive/negative results. Thus 5F was given in form of i.p. instead of oral 
administration in this study. 
Modem in-vivo chemotherapeutic researches employ two major types of tumor 
induction methods: xenograft induction method and chemical one. Xenograft models 
are achieved by injecting primary carcinoma cells into targeted organs of the 
immunocompromised animal model, which is limited to "nude mice", only 
(Voskoglou-Nomikos et al, 2003). The tumors induced are homogenous and 
localized. All tumor cells are identical to the primary cells applied to the organ with 
no variations. The development of the tumor is fast, which implies a short 
experiment turnaround time. The quality of the tumors formed by the primary cells is 
consistent between individuals. The treatment effects of the xenograft tumors are 
significant and are can be easily evaluated by morphological parameters such as 
tumor volume. However, all xenograft tumors retain the properties of cells injected 
such as the morphology of the cells which is different from native organ environment. 
Vascular systems are not found in xenograft models, therefore, the development of 
the tumor is independent to the organ development (Voskoglou-Nomikos et al，2003). 
The genetic characteristics of the cells are constant and stable. The genome of the 
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cells is not subjected to mutations induced by external stimuli such as carcinogens. 
Summerising all the pros and cons stated above, xenograft models are able simulate 
an in vivo environment for the treatment of cell cultures, replacing the culture 
medium with nude mice. The variety of animal species is limited, as 
immunocompromised rats, rabbits, or even larger animals virtually do not exist. On 
the other hand, chemically induced tumors are achieved by administering known 
mutation inducing chemicals, or carcinogens, to trigger the random mutation of the 
target organ to induce tumors. These carcinogens, such as DEN and NNK in this 
study, often have high efficiency and frequency in resulting tumors in the specific 
organ which is, however, strain-specific. In this study, for example, DEN is highest 
in efficiency to induce HCC in C3H strain of mice when compared to BALBc and 
C57 mice, while NNK can induce lung cancer in A/J mice with more than 95% of 
incident rate compared to around half in C3H and BALBc mice (Lee et al, 1991; 
Belinsky et al, 1992). Unlike xenograft models of tumors, chemically induced 
, tumors are relatively poor in assessing the development progress as well as the 
quality of the tumors formed inside the animal models. Although matching the right 
carcinogen with right strain of animal can, in higher probability, yield the highest 
amount of tumors, the efficiency of tumor induction was heavily varied between 
individuals. Maintaining a constant environment can help in minimizing the variation, 
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but the variation still exists. Such variations may create false results and leave 
questions to the validity of the data (Voskoglou-Nomikos et al, 2003). Moreover, 
development time for chemically induced tumors in times longer than xenograft 
models. Since chemical inducing method is featured by accelerating and intensifying 
mutations that cause cancer in organs but not the growth rate of the tumor. Time still 
takes for the growth of tumors. But one fact that xenograft models can never simulate 
is the origin of the tumor induced. Tumors induced by carcinogens are originated 
from the organ, which closely associated and interacted with the organ. The 
environment is most native when compared to the carcinogenesis of normal tumors 
(Ha, 2001). Thus the effect of the treatment truly reflects the efficiency of the 
chemotherapeutic agent in vivo. In this study, the aim was focused on the treatment 
effect and the blueprint of the signaling mechanisms but not the molecular 
mechanism of 5F. It is thus more suitable to deploy a chemically induced model than 
a xenograft model. 
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Chapter 5: Conclusion 
Our study demonstrated that 5F alone is effective against HCC and lung carcinoma 
in-vivo. The effect of 5F is dose-dependent. At high concentrations of 24mg/kg and 
48mg/kg 5F it induced apoptosis in-vivo significantly. 5F is also effective at low 
doses of 12mg/kg and 24mg/kg in combination with 5-FU, but the possible 
antagonistic effect will have to be clarified. Bax and NF-kappa B may serve as the 
major regulatory molecules in 5F-mediated cell death pathway. The regulation of 
iNOS by 5F may be cell type limited. 
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